0001615774-16-005579.txt : 20160523 0001615774-16-005579.hdr.sgml : 20160523 20160523163127 ACCESSION NUMBER: 0001615774-16-005579 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160523 DATE AS OF CHANGE: 20160523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NuGene International, Inc. CENTRAL INDEX KEY: 0001593549 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 493999052 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-192997 FILM NUMBER: 161669425 BUSINESS ADDRESS: STREET 1: 17912 COWAN STREET 2: SUITE A CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: 855-307-2134 MAIL ADDRESS: STREET 1: 17912 COWAN STREET 2: SUITE A CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: Bling Marketing, Inc. DATE OF NAME CHANGE: 20131205 10-Q 1 s103253_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended March 31, 2016

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission File Number 333-192997

NuGene International, Inc.

(Exact name of registrant as specified in its charter)

Nevada		46-3999052
(State of incorporation)		(I.R.S. Employer Identification No.)

17912 Cowan, Suite A, Irvine, California 92614		(949) 468-5116
(Address of principal executive offices)		(Registrant’s telephone number, including area code)

Securities registered under Section 12(b) of the Act:
Title of each class registered:	Name of each exchange on which registered:
None	None

Securities registered under Section 12(g) of the Act: None (Title of class)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and, (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨

Accelerated filer ¨

Non-accelerated filer ¨
(Do not check if a smaller reporting company)

Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No þ

The outstanding number of shares of common stock as of May 20, 2016 was: 40,024,673

Documents incorporated by reference: None

NuGene International, Inc.

Form 10-Q

Table of Contents

PART I. FINANCIAL INFORMATION		3
ITEM 1.	Financial Statements	3
	Condensed Consolidated Balance Sheets at March 31, 2016 (unaudited) and December 31, 2015	3
	Condensed Consolidated Statements of Operations for the three months ended March 31, 2016 and 2015 (unaudited)	4
	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2016 and 2015 (unaudited)	5
	Notes to Condensed Consolidated Financial Statements (unaudited)	6

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	19
ITEM 4.	Controls and Procedures	19

PART II. OTHER INFORMATION		20
ITEM 1.	Legal Proceedings	20
ITEM 1A.	Risk Factors	21
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	37
ITEM 3.	Defaults Upon Senior Securities	38
ITEM 4.	Mine Safety Disclosures.	38
ITEM 5	Other Information	38
ITEM 6.	Exhibits	38
	SIGNATURES	39

PART I

ITEM 1. FINANCIAL STATEMENTS

NuGene International, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

	March 31, 2016 (unaudited)			December 31, 2015

Assets
Current assets:
Cash	$	149,290		$	22,907
Accounts receivable, net of allowance for doubtful accounts of $177,140 on March 31, 2016 and December 31, 2015		383,627			347,048
Inventories		285,482			177,492
Prepaid inventories		85,280			74,046
Prepaid consulting		122,667			-
Other current assets		80,181			26,509

Total current assets		1,106,527			648,002

Property and equipment, net of accumulated depreciation of $54,214 and $40,620 at March 31, 2016 and December 31, 2015, respectively		199,296			208,350
Deposits		21,321			21,321

	$	1,327,144		$	877,673

Liabilities and Stockholders' Deficiency

Current liabilities:
Accounts payable and accrued expenses	$	733,636		$	327,623
Accounts payable and advances - related parties		253,261			37,936
Notes payable and advances		1,200,297			842,504
Accrued interest		92,490			35,052
Other current liabilities		48,555			17,924

Total current liabilities		2,328,239			1,261,039

Commitments and contingencies

Stockholders’ deficiency:
Series A convertible preferred stock; $0.0001 par value; 25,000,000 shares authorized; 1,917,720 shares issued and outstanding on March 31, 2016 and December 31, 2015		192			192
Common stock; $0.0001 par value; 100,000,000 shares authorized; 40,024,673 and 39,894,673 shares issued and outstanding on March 31, 2016 and December 31, 2015, respectively		4,003			3,990
Common stock earned but unissued; 218,116 and 302,283 shares as of March 31, 2016 and December 31, 2015, respectively		42			30
Additional paid-in capital		6,640,257			6,180,929
Accumulated deficit		(7,645,589	)		(6,568,507	)

Total stockholders' deficiency		(1,001,095	)		(383,366	)

	$	1,327,144		$	877,673

See accompanying notes to unaudited condensed consolidated financial statements

NuGene International, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

For the three months ended March 31, 2016 and 2015

(Unaudited)

	2016			2015

Revenues	$	213,298		$	481,360

Cost of goods sold		66,188			177,403

		147,110			303,957

Operating expenses:
Advertising and promotion		57,617			74,077
Personnel		547,378			94,086
Selling, general and administrative		263,037			163,108
Research and development		29,946			51,291
Professional fees		154,389			162,021

Total operating expenses		1,052,367			544,583

Loss from operations		(905,257	)		(240,626	)

Interest expense, net		(171,825	)		-

Net loss	$	(1,077,082	)	$	(240,626	)

Weighted average number of common shares outstanding - basic and diluted		39,959,673			39,197,400

Net loss per share - basic and diluted	$	(0.03	)	$	(0.01	)

See accompanying notes to unaudited condensed consolidated financial statements

NuGene International, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

For the three months ended March 31, 2016 and 2015

(Unaudited)

	2016			2015

Cash flows from operating activities:
Net loss	$	(1,077,082	)	$	(240,626	)
Adjustments to reconcile net loss to cash flows from operating activities:
Stock based compensation and stock issued for services		336,686			40,374
Non-cash portion of interest expense		112,818			-
Depreciation and amortization		13,594			80,172
Bad debt expense		-			2,700
Changes in operating assets and liabilities:
Accounts receivable		(36,579	)		(225,090	)
Inventories		(107,990	)		8,504
Prepaid inventories		(11,234	)		-
Other assets		(53,672	)		(171,481	)
Accounts payable and accrued expenses		406,013			45,833
Accounts payable and advances - related parties		215,325			(96,758	)
Deferred revenues		-			(136,748	)
Accrued interest		57,438			-
Other liabilities		30,631			-

Cash flows from operating activities		(114,052	)		(693,120	)

Cash flows from investing activities:
Purchases of property and equipment		(4,540	)		(82,699	)

Cash flows from financing activities:
Proceeds from issuance of notes payable		244,975			-
Proceeds from issuance of common stock		-			50,000

Cash flows from financing activities		244,975			50,000

Change in cash		126,383			(725,819	)

Cash, beginning of period		22,907			1,344,737

Cash, end of period	$	149,290		$	618,918

Supplemental disclosure of cash flow information:
Cash paid for:
Interest	$	-		$	-
Income taxes	$	-		$	-

Supplemental disclosure for non-cash activities:
Prepaid consulting	$	128,000		$	-

See accompanying notes to unaudited condensed consolidated financial statements

NUGENE INTERNATIONAL, INC

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2016

NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION

NuGene International, Inc. (the “Company” or “NGI”) was incorporated in the State of Nevada on October 31, 2013. NuGene, Inc. (our wholly owned subsidiary) was incorporated in the state of California in December 2006. On January 20, 2015, we formed NuGene BioPharma, Inc. (“BioPharma”) as a wholly owned California incorporated subsidiary of NGI. On November 6, 2015, we formed The Aesthetic Group, Inc. (“TAG”) as a wholly owned California incorporated subsidiary of NGI. Both BioPharma and TAG had no significant independent operations during 2015.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of our Company have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and applicable regulations of the U.S. Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been omitted pursuant to such rules and regulations. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of financial position and results of operations have been included. Our operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2015, which are included in our Annual Report on Form 10-K.

The accompanying condensed consolidated financial statements reflect the accounts of NuGene International, Inc. and its wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

We have incurred net losses through the date of these financial statements and have yet to establish profitable operations. Our financial statements have been presented on the basis that our business is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We are subject to the risks and uncertainties associated with a business with high short-term debt, limited commercial product revenues, including limitations on our operating capital resources and uncertain demand for our products. We have incurred recurring operating losses and negative operating cash flows in 2015 and through March 31, 2016, and we expect to continue to incur operating losses and negative operating cash flows at least through the near future. Members of our Company’s management have been required to advance our Company funding in order to partially meet our most critical cash requirements including payroll along with those associated with certain critical goods and services. In the process of managing these situations, our management may have made representations implying their personal guarantee of certain of our Company’s obligations, irrespective of whether such guarantees are legally valid and enforceable.

As a result of the aforementioned factors, management has concluded that there is substantial doubt about our ability to continue as a going concern. Our independent registered public accounting firm, in its report on our 2015 consolidated financial statements, raised substantial doubt about our ability to continue as a going concern. Our consolidated financial statements as of and for the three months ended March 31, 2016 do not contain any adjustments for this uncertainty. In response to our Company’s cash needs, we raised funding as described in our footnotes that follow. Any additional amounts raised will be used for our future investing and operating cash flow needs. However, there can be no assurance that we will be successful in raising additional amounts of financing.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2015 Annual Report.

Use of Estimates

Conformity with Generally Accepted Accounting Principles (“GAAP”) requires the use of estimates and judgments that affect the reported amounts in the financial statements and accompanying notes. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities that are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. GAAP requires us to make estimates and judgments in several areas, including but not limited to, those related to revenue recognition, collectability of accounts receivable, contingent liabilities, fair value of financial instruments, fair value of acquired intangible assets and goodwill, useful lives of intangible assets and property and equipment, excess and obsolete inventory, deferred tax asset valuation and income taxes. These estimates are based on management’s knowledge about current events and expectations about actions we may undertake in the future. Actual results could differ materially from those estimates.

Reclassifications

For comparability, certain prior period amounts have been reclassified, where appropriate, to conform to the current year’s financial statement presentation. These reclassifications have no impact on net loss.

Concentration of Revenues

During the three months ended March 31, 2016, we derived 18% of our revenues from one customer. During the three months ended March 31, 2015, we derived 46% of our revenues from a single wholesale distributor. Our distributors purchase products from us on a purchase order basis on standard terms. The distributors are under no obligation to continue to purchase our products. The loss of any of our major distributors, a material reduction in their purchases or the cancellation of product orders or unexpected returns of unsold products could significantly decrease our revenues and impede our future growth prospects. We do not have long-term purchase commitments with our distributors.

Research and Development

Internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed. Research and development consists of consulting fees, direct labor and raw materials associated with the development of new products to be commercialized by our Company. Research and development expenses totaled $29,946 and $51,291 for the three months ended March 31, 2016 and 2015, respectively.

Allowance for Doubtful Accounts

Our Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Our allowance for doubtful accounts was $177,140 at March 31, 2016 and December 31, 2015. Bad debt expense totaled $2,700 for the three months ended March 31, 2015. At March 31, 2016, we have $327,893 outstanding in accounts receivable from one customer. This balance represents 85.5% of net accounts receivable at March 31, 2016, and none of this balance is included in our allowance for doubtful accounts as of that date. The products represented by this outstanding balance were shipped in December 2015 under extended payment terms of 90 days. As of March 31, 2016, the invoice was past due, however management believes that the full account is recoverable.

Prepaid Consulting

Prepaid consulting represents amounts paid with restricted stock awards for future contractual benefits to be received. The fair value of these restricted stock awards is recorded to prepaid consulting and additional paid-in capital, upon issuance of the shares, and then amortized to the statements of operations over the life of the contracts using the straight-line method. On March 17, 2016, the Company entered into a 12 month consulting arrangement with an unrelated party. The Company granted 200,000 shares which were valued based upon the Company’s closing price on the date of grant. The Company recorded prepaid consulting of $122,667 as of March 31, 2016 and the Company recognized SGA totaling $5,333 for the three months ended March 31, 2016 in connection with this agreement.

Recent Accounting Standards Updates

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842). ASU No. 2016-02 requires an entity to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. ASU No. 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. The Company currently in the process of evaluating the impact of adoption of ASU No. 2016-02 on the condensed consolidated financial statements and related disclosures.

In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations”. The purpose of ASU No. 2016-08 is to clarify the implementation of guidance on principal versus agent considerations. The amendments in ASU No. 2016-08 are effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently assessing the impact of ASU No. 2016-08 on the condensed consolidated financial statements and related disclosures.

In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. The amendment is to simplify several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in ASU No. 2016-09 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company is currently assessing the impact of ASU No. 2016-09 on the condensed consolidated financial statements and related disclosures.

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. Our Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

NOTE 3 – INVENTORIES

Inventories consist of the following:

	March 31, 2016		December 31, 2015
Raw materials	$	81,083	$	72,287
Finished goods		204,399		105,205
Total Inventories	$	285,482	$	177,492

NOTE 4 – INTANGIBLE ASSETS

Licensee Agreement

In November 2014, we entered into a License Agreement with kathy ireland Worldwide^® ("kiWW^®") under which we licensed the right to utilize the trademarks and rights to the name, likeness and visual representations of Kathy Ireland (“KI”) in connection with our cosmeceutical line of products. The initial term of the license is for eight years and it may be renewed at the option of our Company for up to an additional four years. In accordance with the License Agreement, we will pay 5% of the net sales for all licensed products sold and collected under the licensed marks or a minimum guaranteed royalty of $100,000 in year one, which includes the period from approximately November 4, 2014 through December 31, 2015 (“Contract Year 1”) of the License Agreement. The minimum guaranteed royalty increases $50,000 each year in years two through eight of the License Agreement. We recognized $50,000 and $100,000 in royalty fees during the three months ended March 31, 2016 and the year ended December 31, 2015, respectively.

Additionally, we are obligated to pay an annual Brand Participation Fee to kiWW^®which provides for general advertising, good will and promotion of the KI brand. NuGene prepaid kiWW $350,000 effective upon execution of the License as a Brand Participation fee for Contract Year 1. The Brand Participation Fee for Contract Years 2 through 8 is $50,000 annually (Year 2 having been completely recognized in the three months ended March 31, 2016) with an additional 1% of the total gross sales of Licensed Products of the prior year beginning in Contract Year 4. Our Company is currently in arrears with respect to the payment of the Year 2 fee that was due in November 2015. Such payment arrears could be construed as an event of default under the License Agreement and could be a cause for its annulment.

NOTE 5 – PROPERTY AND EQUIPMENT

Property and equipment, net consist of the following:

	March 31, 2016			December 31, 2015
Software / website development	$	8,219		$	8,219
Equipment		141,125			136,585
Leasehold improvements		104,166			104,166
Property and equipment, gross		253,510			248,970
Accumulated depreciation		(54,214	)		(40,620	)
Property and equipment, net	$	199,296		$	208,350

Depreciation expense for the three months ended March 31, 2016 and 2015 was $13,594 and $5,172, respectively.

NOTE 6 – PROMISSORY NOTES PAYABLE AND ADVANCES

On September 25, 2015, we entered into a Securities Purchase Agreement and issued a 15% Promissory Note with the principal face value of $500,000 (the “15% Note”) to an accredited investor. Under the terms of the 15% Note, all principal and related accrued interest outstanding are due and payable to the noteholder upon the earlier of: (i) September 25, 2016; or (ii) within ten business days after the consummation of an equity or convertible debt financing with aggregate gross proceeds of at least $1,000,000.

Borrowings made pursuant to the 15% Note bear interest at the annual rate of 15% (or $75,000), irrespective of whether paid at or prior to September 25, 2016. If any amount payable pursuant to the note payable is not paid when due (without regard to any applicable grace periods as set forth in the Note), whether at stated maturity, by acceleration or otherwise, such overdue amount shall bear interest at the rate of 15% from the date of such non-payment until such amount is paid in full. We recognized $ 43,521 in interest expense during the three months ended March 31, 2016 based on an estimated repayment date of April 4, 2016 (see subsequent events footnote below).

During November 2015, we issued a one year 10% promissory notes payable (the “10% Note”) to a purchaser for cash proceeds totaling $50,000. In the event that we secure any future financing with aggregate gross proceeds of at least $1 million while the 10% Note is outstanding, the 10% Note and all accrued interest therefrom will be immediately due and payable within ten business days of the closing of such financing. The holder may also convert any unpaid principal under the 10% Note into any funding instrument entered into by our Company for a period of 180 days after the date of the 10% Note. The full interest of 10% of the borrowings under the 10% Note ($5,000) is due irrespective of whether paid at maturity or when required to be prepaid. We have recognized $2,420 in interest expense during the three months ended March 31, 2016 based on an estimated repayment date of May 15, 2016.

On November 30, 2015 and on four subsequent dates during December 2015, four individuals (the “Lenders”) advanced a total of $410,000 to the Company. The borrowings (“Advances”) were not accompanied by documentation of the nature of the Advances. However, there were general discussions as to the repayment terms, the interest expected to be paid to the Lenders and additional equity of the Company to be issued to the Lenders in connection with the Advances. Accordingly, we have accounted for the Advances based on estimates of their still undocumented final terms.

On March 30, 2016, a corporation advanced our Company $244,975. The advance was undocumented but our Company subsequently entered into an agreement with the corporation on terms documented in the subsequent events footnote that follows. The amounts advanced were accounted for at the value of the cash received as of March 31, 2016.

In connection with the expected value of the warrants, we recorded an equity contribution of $138,333 in December 2015 ($82,351 and $15,259 of which was amortized and charged to interest expense during the three months ended March 31, 2016 and December 31, 2015, respectively). We calculated an original issue discount of $51,111 on the borrowings ($30,467 of which was charged to interest expense during the three months ended March 31, 2016) and we have recognized $11,496 of interest during the three months ended March 31, 2016 for the expected interest to be paid on the non-discounted face value of the borrowings.

Borrowings under notes payable and advances as of March 31, 2016 and December 31, 2015 are summarized as follows:

	Company Proceeds		Carrying Value at March 31, 2016		Carrying Value at December 31, 2015		Accrued Interest at March 31, 2016		Accrued Interest at December 31, 2015		Principal Value at Maturity

15% Note	$	500,000	$	500,000	$	500,000	$	75,000	$	31,479	$	500,000
10% Note		50,000		50,000		50,000		3,803		1,383		50,000
Advances - 2015		410,000		405,322		292,504		13,687		2,190		461,111
Advances - 2016		244,975		244,975		-		-		-		275,000
	$	1,204,975	$	1,200,297	$	842,504	$	92,490	$	35,052	$	1,286,111

NOTE 7 – STOCKHOLDERS’ EQUITY

Common Stock

Our Company has Advisory Agreements with members of its Advisory Board. The terms of the individual Advisory Agreements vary and provide for up to 50,000 initial sign-on shares vesting for a maximum of an 18-month period, and up to 50,000 shares of common stock per annum issued on the anniversary of the effective date of the agreement. Expenses for the issuance of common stock for services related to these share issuances is recognized over the service period in which the shares are earned or over the respective vesting period, as applicable, and is calculated based on the average closing price per share of our common stock, during the respective quarter, as quoted on the OTC Marketplace. Selling, general and administrative expenses (“SGA”) recognized in connection with the Advisory Agreements totaled $36,398 and $40,374 for the three months ended March 31, 2016 and 2015, respectively.

On March 17, 2016, we entered into a consulting agreement for services over one year. In connection with the agreement, we granted the consultant 200,000 shares of our fully vested common stock as consideration for the consultant’s services. The Company recorded prepaid consulting of $122,667 as of March 31, 2016 and the Company recognized SGA totaling $5,333 for the three months ended March 31, 2016 in connection with this agreement.

Common Stock Options

On August 14, 2015, we granted an option to purchase up to 1,000,000 shares of our common stock to each of two employees. We recognized $294,955 of SGA as stock based compensation in connection with the vesting of the options during three months ended March 31, 2016.

Common Stock Warrants

Our Company has issued warrants to purchase shares of our common stock to accredited investors and consultants as compensation for services rendered, as well as, in conjunction with the purchase of our common stock. A summary of the Company’s warrants activity and related information as of March 31, 2016 is as follows.

Stock Warrants Outstanding as of March 31, 2016
Exercise		Warrants		Remaining		Warrants
Price		Granted		Life (Years)		Exercisable
$	0.001		1,350,000		1.72		450,000
$	1.50		50,000		2.62		50,000
$	2.00		300,000		4.63		300,000
$	2.50		500,000		5.00		-
			2,200,000				800,000

NOTE 8 – RELATED PARTY TRANSACTIONS

The following individuals and entities have been identified as related parties based on their affiliation with our CEO and Chairman of the Board:

Ali Kharazmi		Chief Executive Officer, President, Board Member and greater than 10% shareholder
Saeed Kharazmi		Chairman of the Board, Acting Chief Financial Officer and greater than 10% shareholder
Genetics Institute of Anti-Aging		Company with common ownership and management
Applied M.A.K. Enterprises, Inc. (“MAK”)		Company with common ownership and management
Advanced Surgical Partners, LLC (“AdvSP”)		Company with common ownership and management
Center for Weight Management & Plastic Surgery (“CWM”)		Company with common ownership and management
Center for Regenerative Science, LLC		Company with common ownership and management

The following amounts were owed to related parties, affiliated with the CEO and Chairman of the Board, at the dates indicated:

	March 31, 2016
AdvSP	$	178,044
CWM		34,000
Ali Kharazmi		14,029
Saeed Kharazmi		27,188
Accounts payable - related parties	$	253,261

The amount owed to AdvSP relates to legal and administrative services provided by AdvSP employees to our Company. Our Company temporarily advanced $95,000 to AdvSP prior to December 31, 2015 and was repaid in full prior to January 5, 2016. The amount owed to CWM relates to medical procedures provided to NuGene consultants as compensation for advertising and marketing services provided to NuGene. The amount owed to Ali and Saeed Kharazmi and all amounts outstanding represent advances that bore no interest and were due on demand or expense reimbursements incurred in the ordinary course of business.

NOTE 9 – COMMITMENTS AND CONTINGENCIES

Commitments

We sub-lease our sole corporate facilities at 17912 Cowan, Suite A, Irvine, California, 92614 from AdvSP, an affiliate of our Company, for approximately $16,637 per month (including common area maintenance), consistent with the amount that is charged to AdvSP by the property owner. On February 5, 2015, AdvSP entered into a new five-year lease for the property with the owner beginning July 1, 2015 and subsequently amended to begin June 1, 2015. The lease was subsequently amended to increase the square footage under lease beginning in January 2016. The lease includes annual increases in the monthly lease payments of approximately 3% each year.

At March 31, 2016, aggregate future minimum payments under the lease, including common area maintenance costs, are as follows:

2016 (remainder)	$	145,670
2017		198,935
2018		204,585
2019		210,234
2020		106,530
Total	$	865,954

During the three month ended March 31, 2016 and 2015, we incurred rent expense totaling $49,913 and $36,000, respectively.

Delinquent Payroll Tax Payments/Returns

The Company is delinquent in filing certain payroll tax returns resulting in the non-payment of the related withholdings and employer taxes. The delinquency and non-payments are for the quarterly period ended March 31, 2016. The total amount of money owed (excluding potential late filing and late payment penalties) at March 31, 2016 is approximately $70,000 (which is included in “accounts payable and accrued expenses” in the accompanying consolidated balance sheet at March 31, 2016).

Legal Proceedings

On July 10, 2015 Stemage Skin Care, LLC (the “Plaintiff”) filed a complaint in the U.S. District Court for the Central District of California entitled “Stemage Skin Care LLC, a North Carolina limited liability company vs. NuGene International, Inc. et al.” (Civil Action No.8:15-cv-01078-AG-JCG). The complaint also names as defendants NuGene, Inc., Ali Kharazmi, Saeed Kharazmi, Kathy Ireland Worldwide, Stephen Roseberry, Steve Rosenblum and Erik Sterling. The complaint contains allegations of damage asserted to be grounded on: (i) copyright infringement; (ii) interference with contract; (iii) intentional interference with prospective economic advantage; (iv) negligent interference with prospective economic advantage; and (v) conspiracy. The complaint allegedly arises out of an August 20, 2012 agreement among the Plaintiff and kathy ireland inc. ("KI") pursuant to which KI made Kathy Ireland available to perform “Ambassador Services" as defined within that agreement. That agreement effectively terminated in October 2014 and is the subject of a separate arbitration with KI and Kathy Ireland before the American Arbitration Association. We filed a response denying all claims and based on our review of the matter, we believe that the complaint is without merit. Early stages of discovery have been completed and we have agreed to stay further discovery and motions during settlement discussions between Plaintiff and KI. Notwithstanding, no assurance of outcome currently can be given.

On July 31, 2015 Star Health & Beauty, LLC (“SH&B”) filed a complaint in the U.S. District Court for the Northern District of Georgia entitled “Star Health & Beauty, LLC vs. NuGene, Inc. and NuGene International, Inc. Defendants” (Case No. 1:15-cv-02634-CAP). The complaint alleges that our use of the NUGENE name and trademark infringes on SH&B’s NUGEN name. SH&B seeks cancelation of our NUGENE trademark, as well as unspecified monetary damages. We are in the process of early discovery to assist us in evaluating the merits of this lawsuit and intend to defend our intellectual property rights vigorously. As this matter is at an early stage, no assurance of outcome currently can be given.

In October 2015, NSE Products, Inc., (“NSE”) a Delaware corporation based in Provo, Utah, initiated actions in the US Patent and Trademark Office contesting several of the Company's trademark registrations and applications. These actions, including Oppositions to trademark applications and Petitions to Revoke registered marks, rely on assertions made by NSE regarding the purported likelihood of confusion and dilution of NSE's trademarks that include the words NU SKIN. The Parties are discussing favorable settlement terms and we expect the matter will be resolved soon.

In May 2016, we were informed that the California Labor Commissioner scheduled a hearing in connection with two individuals that claimed our Company did not fulfill its obligations to pay a final paycheck. The two individuals are seeking back pay and penalties totaling approximately $31,000. Although we intend to contest various aspects of each claim, we recognize our Company may be held liable and accrued our best estimate of the eventual amount of the settlement.

On May 6, 2016, we were presented with a demand for payment of compensation for a former executive employee (the “Executive”) pursuant to his employment contract with our Company. The amount of the compensation claimed by the Executive totaled $49,998. Our Company’s management is evaluating the merits of this matter. No amounts have been accrued in connection with this matter through March 31, 2016 as it reflected the Executive’s termination of employment on April 6, 2016.

From time to time, we may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate) may materially and adversely affect our financial condition, results of operations and liquidity. In addition, the ultimate outcome of any litigation is uncertain. Any outcome (including any for the actions described above), whether favorable or unfavorable, may materially and adversely affect us due to legal costs and expenses, diversion of management attention and other factors. We expense legal costs in the period incurred. We cannot assure you that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against us in the future, and these matters could relate to prior, current or future transactions or events.

Other than that described above, we are not currently a party to any other material legal proceedings. We are not aware of any pending or threatened litigation against us that in our view would have a material adverse effect on our business, financial condition, liquidity, or operating results. However, legal claims are inherently uncertain, and we cannot assure you that we will not be adversely affected in the future by legal proceedings.

NOTE 10 – SUBSEQUENT EVENTS

On April 4, 2016, we issued a note payable to Canyon Assets Holdings, Inc. (“Lender”) dated March 28, 2016 in the principal amount of $575,000. The note was issued to the Lender in consideration for the Lender’s having satisfied on the Company’s behalf an outstanding note payable (the “CAH Note”) of the Company (the “JTS Note”). The JTS Note issued September 25, 2015 was repaid in full ($500,000 face value and accrued interest of $75,000) by the Lender with the payment of $575,000 in cash. The terms of the CAH Note call for an interest rate of 15%, due one year from the date of the CAH Note. However, all accrued and unpaid interest and all other amounts payable under the CAH Note are due to the Lender within ten (10) business days after the closing by the Company of an equity or convertible debt financing in one or more series of transactions, with aggregate gross proceeds of at least $1 million.

On April 4, 2016, we issued a $275,000 face value note payable and 50,000 shares of our common stock to Gemini Master Fund, LTD (“Gemini”) pursuant to a Security Purchase Agreement dated March 30, 2016 (the date the funds were received by our Company). Under the terms of the related note payable (the “Gemini Note”), the Company received $245,000, net of costs and original issue discount. Other significant terms of the Gemini Note include:

A maturity date of December 31, 2016 in the absence of events triggering mandatory early repayment (as summarized below);

Interest accrues at the rate of 8% on the $275,000 face value (18% in the event of an event of default as defined in the Gemini Note);

The Gemini Note is convertible in part (subject to a $10,000 minimum) at the option of Gemini into shares of the Company’s common stock at the rate of $0.70 per share (subject to adjustment summarized below);

The Company has the option to prepay the Gemini Note;

All prepayments of the Gemini Note, whether effected at the option of the Company or subject to mandatory early repayment (as summarized herein), require the Company to repay Gemini 112% of the outstanding principal and all outstanding accrued interest through the date of prepayment;

All principal and interest outstanding under the Gemini Note are required to be immediately repaid should the Company complete a financing or series of financings totaling $1.5 million or more; and

The Conversion price of the Gemini Note is adjusted for the following: 1) loss of Company DTC eligibility – conversion price adjusts to $0.25 per share; 2) stock dividends and splits – as described in the Gemini Note; 3) a rights offering below the market price (as defined) – as described in the Gemini Note; 4) fundamental transactions (as defined) – as described in the Gemini Note; 5) subsequent equity sales below $0.70 per share – as more particularly detailed and described in the Gemini Note.

The foregoing summaries of the agreements and of the CAH Note and Gemini Note are qualified in by the forms of the agreements included as exhibits to this report. The cash received prior to March 31, 2016 on the Gemini Note were included in notes and advances payable in the accompanying balance sheet as of that date.

In May 2016, we entered into agreements with two employees that hold options to purchase up to 1,000,000 shares of our common stock each. The agreements modified the strike price of their outstanding options from the previous strike prices of $1.50 to $0.55 per share. All other terms of the previous option agreements remained unchanged.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, including "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 2 of Part I of this report include forward-looking statements. Information in this report contains “forward looking statements” which may be identified by the use of forward-looking terminology, such as “may”, “shall”, “will”, “could”, “expect”, “estimate”, “anticipate”, “predict”, “probable”, “possible”, “should”, “continue”, “believes”, “estimates”, “projects”, “targets”, or similar terms, variations of those terms or the negative of those terms. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guaranty, or warranty is to be inferred from those forward-looking statements. Statements in this report concerning the following are forward looking statements:

future financial and operating results;

our ability to fund operations and business plans, and the timing of any funding or corporate development transactions we may pursue;

the ability of our suppliers to provide products or services in the future of an acceptable quality on a timely and cost-effective basis;

expectations concerning market acceptance of our products;

current and future economic and political conditions;

overall industry and market trends;

management’s goals and plans for future operations; and

other assumptions described in this report underlying or relating to any forward-looking statements.

The assumptions used for purposes of the forward-looking statements specified in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives requires the exercise of judgment. To the extent that the assumed events do not occur, the outcome may vary substantially from anticipated or projected results, and, accordingly, no opinion is expressed on the achievability of those forward-looking statements. No assurance can be given that any of the assumptions relating to the forward-looking statements specified in the following information are accurate, and we assume no obligation to update any such forward-looking statements. Unless otherwise noted, the terms "NGI", the "Company", "we", "us", and "our" refer to the ongoing business operations of NuGene International, Inc. and our wholly-owned subsidiaries, NuGene, Inc. and NuGene BioPharma, Inc., as well as, the past operations of NuGene, Inc.

RESULTS OF OPERATIONS

The following analysis of the results of operations for the three months ended March 31, 2016 and 2015 should be read in conjunction with our financial statements and the notes to those financial statements that are included elsewhere in this Quarterly Report on Form 10-Q. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements because of a number of factors. An investment in our common stock involves a high degree of risk. Readers of this Quarterly Report on Form 10-Q should carefully consider the risks set forth in the Risk Factors and Business sections of our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 30, 2016, as well as those Risk Factors set out in Part II, Item 1A below. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” or similar expressions, variations of those terms or the negative of those terms to identify forward-looking statements. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guaranty, or warranty is to be inferred from those forward-looking statements.

The assumptions used for purposes of the forward-looking statements specified in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives require the exercise of judgment. To the extent that the assumed events do not occur, the outcome may vary substantially from anticipated or projected results, and, accordingly, no opinion is expressed on the achievability of those forward-looking statements. No assurance can be given that any of the assumptions relating to the forward-looking statements specified in the following information are accurate, and we assume no obligation to update any such forward-looking statements.

Sales.

Sales generated during the three months ended March 31, 2016 totaling $213,298 resulted primarily from the sale of our cosmeceutical products to wholesale distributors, including 18% of our revenues to one customer. Our customers generally purchase products from us on a purchase order basis on standard terms (with the notable exception of a large sale to one customer in the fourth quarter of 2015) but future product sales will be tied directly to their success in reselling our products. Our customers are under no obligation to continue to purchase our products. The loss of significant customers, a material reduction in their purchases or the cancellation of product orders or unexpected returns of unsold products could significantly decrease our revenues and adversely affect our future growth prospects. We do not have long-term purchase commitments from our customers.

During the three months ended March 31, 2015, our Company had sales totaling $481,360, 46% of which was sold to one customer. Our sales in 2016 decreased 268,062 or 55% from the same period in 2015. While our sales decrease could be attributed in part to decreases in customer demand for our products of which we are unaware at present, we believe our severe lack of liquidity was a significant contributing factor. Our inability to maintain our balances current with our suppliers hampered our ability to procure the ingredients needed to produce our products. Additionally, our cash constraints made it difficult to afford and to recruit qualified senior level employees, especially in the area of marketing. Our plans for launching a television direct marketing campaign have also been delayed for the same reasons. We estimate that absent successful procurement of the funding that we currently seek, we will be unable to build sales in accordance with our corporate plans and sales could continue to be stagnant or decrease significantly.

Cost of Goods Sold.

Cost of goods sold during the three months ended March 31, 2016 totaled $66,188 and represented 31% of sales. These costs consisted primarily of the cost of raw materials, product packaging, and direct labor used in the manufacture of our cosmeceutical products, as well as shipping and handling. Cost of goods sold during the same period in 2015 totaled $177,403, or 37% of sales. Our products sell for margins comparable with others in industries similar to ours. Our margins will reflect our efficiency in the production of our products, the desirability of our products and our ability to grow sales in order to scale our operations. Our relationships with our suppliers will also be important in procuring materials at better pricing and our aforementioned liquidity challenges could significantly affect such relationships.

Expenses.

Advertising and promotion.

Advertising and promotion totaled $57,617 for the three months ended March 31, 2016 compared to $74,077 during the same period in 2015. This represented a decrease of $16,459 or 22% from 2015 to 2016. The majority of these expenses in 2016 were for marketing consultants and brand management expenses ($55,326). The decrease in the non-marketing related portion of advertising and promotion was primarily attributable to our Company’s lack of available funding to carry on our planned advertising and promotion of our product.

Personnel.

Personnel expenses of $547,378 increased $453,292 for the first quarter of 2016 (482% or nearly six times) from the first quarter of 2015 ($94,086). The increase in personnel expenses was attributable to additional employees on board in 2016 (including several highly compensated executives) that were not employed in 2015. Included in personnel costs was stock based compensation (a noncash expense) that increased from $40,374 in 2015 to $331,353 in the first quarter of 2016, an increase of $290,979 or over 7.2 times the prior year’s amount. In both 2015 and 2016, our Chief Executive Officer and Chief Financial Officer neither accrued nor received any compensation for services rendered to our Company. Personnel expenses do not include direct labor charged directly to products we manufacture.

Included in personnel expenses are our Company’s share of payroll taxes totaling $29,389 in 2016. As previously noted, our Company has not remitted neither its share of payroll tax expenses nor the amounts withheld from employees’ paychecks during the months of February, March and April 2016.

Selling, general and administrative.

Selling, general and administrative expenses (“SGA”) totaled $263,037 for the three months ended March 31, 2016 compared to $163,108 for the three months ended March 31, 2015. This was an increase of $99,929 or more than 61%. Included in SGA was $5,333 stock based payment for the three months ended March 31, 2016 as the grant of 200,000 shares of our common stock to a consultant (no comparable expense was incurred in 2015). SGA also included $43,321 in insurance expense (2015 - $9,246) and $49,913 in rent expense (2015 - $36,000).

Research and development.

Expenses related to research and development totaled $29,946 for the three months ended March 31, 2016 compared to $51,291 for the corresponding period in 2015. This represented a decrease of $21,345 or 42% year over year. The decrease in the in research and development expense was primarily attributable to our Company’s lack of available funding to carry on our planned advertising and promotion of our product.

Professional fees.

Professional fees totaled $154,389 for the three months ended March 31, 2016 compared to $162,021 for the three months ended March 31, 2015. This represented a decrease of $7,633 or nearly 5%. A significant decrease in accounting and auditing expenses in excess of $30,000 due to the lack of merger related costs in the current year was offset by increased legal expenses of $62,241 in 2016 compared to $27,942 in 2015. The $34,299 increase (123%) in 2016 was primarily due to the legal fees in connection with litigation matters (discussed elsewhere) and the cost of our in-house attorney.

Interest expense.

Interest expense arose as a result of our borrowings outstanding during the three months ended March 31, 2016 (there were no interest bearing liabilities in the comparable period of 2015). While there was no cash interest due during the period, interest expense resulted from the accretion to face value of borrowings advanced to our Company in December 2015 as well as accruing interest on all debt outstanding. Interest of $171,825 on the December 31, 2015 carrying value of the notes payable and advances of $842,504. This reflects our Company’s poor credit worthiness and need to resort to very high cost borrowing in order to procure the funding necessary to maintain our Company’s operations.

Net Loss.

We reported a net loss of $1,077,082 during the three months ended March 31, 2016 compared to a net loss of $240,626 in the comparable period of 2015.

Liquidity and Capital Resources.

We have incurred recurring operating losses and negative operating cash flows in 2015 and through March 31, 2016, and we expect to continue to incur operating losses and negative operating cash flows at least through the near future. Members of our Company’s management have been required to advance our Company funding in order to partially meet our most critical cash requirements including payroll along with those associated with certain critical goods and services. In the process of managing these situations, our management may have made representations implying their personal guarantee of certain of our Company’s obligations, irrespective of whether such guarantees are legally valid and enforceable.

Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Inflation

Inflation and changing prices have had no material effect on our net sales and revenues or on our income from continuing operations over our two most recent fiscal years.

Critical Accounting Policies and Estimates

Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to the fair market value of our assets and accrued stock-based compensation expense. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. In making estimates and judgments, management employs critical accounting policies.

For a description of our critical accounting policies, please see Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2015. There have not been any material changes to our critical accounting policies since December 31, 2015.

ITEM 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4: CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e)) under the Exchange Act) that is designed to ensure that information required to be disclosed by our Company in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time specified in the Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Pursuant to Rule 13a-15(b) under the Exchange Act, our Company carried out an evaluation with the participation of our Company's management, including our Company's Chief Executive Officer ("CEO") and our Company's Acting Chief Financial Officer ("Acting CFO"), of the effectiveness of our Company's disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of March 31, 2016. Based upon that evaluation, our Company's CEO and Acting CFO concluded that our Company's disclosure controls and procedures were not effective as of March 31, 2016 due to our Company’s limited internal resources and lack of ability to have multiple levels of transaction review.

Management is in the process of determining how best to change our current system and implement a more effective system to insure that information required to be disclosed in the reports that we file or submit under the Exchange Act have been recorded, processed, summarized and reported accurately. Our management intends to develop procedures to address the current deficiencies to the extent possible given limitations in financial and personnel resources. While management is working on a plan, no assurance can be made at this point that the implementation of such controls and procedures will be completed in a timely manner or that they will be adequate once implemented.

Changes in internal control over financial reporting

There have been no changes in our internal control over financial reporting during the three months ended March 31, 2016 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II: OTHER INFORMATION

ITEM 1: LEGAL PROCEEDINGS

Legal Proceedings

ITEM 1A: RISK FACTORS

An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below, together with all of the other information included in this Quarterly Report before making an investment decision. Our future operating results may vary substantially from anticipated results due to a number of risks and uncertainties, many of which are beyond our control. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. The following discussion highlights some of these risks and uncertainties and the possible impact of these risks on future results of operations. If any of the following risks occur, our business, financial condition or results of operations could be materially and adversely affected. In that case, the market value of our stock could decline substantially and you could lose part or all of your investment.

RISKS RELATED TO OUR BUSINESS

Our products and product candidates may not achieve or maintain widespread market acceptance.

We may not achieve or maintain widespread market acceptance of our products or product candidates among physicians, patients or healthcare providers. Our products are highly susceptible to physician and patient preference and market acceptance. We have a limited history of promoting our cosmeceutical products. Significant marketing efforts to date have been focused primarily on dermatologists and plastic surgeons.

We believe that market acceptance of our products will depend on many factors including:

The perceived advantages of our products over competing products;

The effectiveness of our sales and marketing efforts;

The convenience and ease of administration of our products;

The safety and efficacy of our products and the prevalence and severity of any possible adverse side effects;

The availability and success of alternative treatments;

Our product pricing and cost effectiveness;

Publicity concerning our products, product candidates or competitive products;

Whether or not patients routinely use our products and purchase additional product, and

Our ability to respond to changes in physician, aestheticians and patient preferences for the treatment of dermatological conditions and the improvement of the appearance of skin.

If our products fail to achieve or maintain market acceptance or if new products or technologies are introduced by others that are more favorably received than our products, are more cost effective or that otherwise render our products obsolete, we may experience a decline in the demand for our products.

If we are unable to market and sell our products successfully, our business, financial condition, results of operation and future growth would suffer. Our ability to compete depends upon the success of our business development activities and our ability, and the ability of our collaborators, to innovate, develop and commercialize new products and product enhancements, as well as to identify new markets for our products

Our business strategy requires us to develop or acquire new and innovative applications of our products, identify new markets for our existing products, and develop or acquire new technology. We are currently developing products for the treatment of burns and exploring several delivery technologies to improve our existing products. However, our development efforts may not lead to new commercial products. To successfully expand our product offerings, we must:

Develop or acquire new products that either add to or significantly improve our current product lines;

Convince our target customers that any new cosmeceutical products or line extensions would be an attractive revenue-generating addition to their practices;

Protect our products with defensible intellectual property; and

Satisfy and maintain all regulatory requirements for commercialization.

The process of developing product candidates involves a high degree of risk and may take several years. Product candidates we may acquire or license in the future that appear promising in the early phases of development may fail to reach the market for several reasons, including:

Pharmaceutical product candidates may fail to receive regulatory approvals required to bring the products to market;

Manufacturing costs or other factors may make our pharmaceutical and cosmeceutical product candidates uneconomical;

The proprietary rights of others and their competing products and technologies may prevent our product candidates from being commercialized;

Success of pharmaceutical product candidates in nonclinical and early clinical studies does not ensure that later stage clinical trials will be successful;

The length of time necessary to complete clinical trials and to submit an application for marketing approval of pharmaceutical product candidates for a final decision by a regulatory authority varies significantly and may be difficult to predict; and

Developing pharmaceutical and cosmeceutical product candidates is very expensive and will have a significant impact on our operating expenses.

We may be unable to continue to develop new products, enhancements to our existing products and other technologies in the near term, if at all, in part because new products or enhancements to our existing products must meet regulatory standards and receive requisite regulatory approvals.

Our failure to introduce new products or enhancements to our existing products for any one of these reasons could adversely affect our expected growth rate and adversely affect our overall business and financial results.

Our marketed products and our products under development could be rendered obsolete by technological or medical advances.

The development of medical advances to treat the conditions that our products are designed to address may render our marketed products and our products under development obsolete or uneconomical. The enhancement to the appearance of skin, the regeneration of hair growth and the treatment of burns, acne or other skin disorders are the subjects of active research and development by many potential competitors, including major pharmaceutical companies, specialized biotechnology firms, universities and other research institutions, as well as other major cosmeceutical companies which develop wrinkle reduction or age defying skin and hair care products. While we intend to expand our technological capabilities to remain competitive, research and development by others may render our technology or products obsolete or noncompetitive or result in treatments superior to any therapy we develop.

Technological advances affecting costs of production also could adversely affect our ability to sell products. Our products could become more expensive to produce, or not competitive, which would decrease our revenues and adversely affect our results of operations and financial condition.

During 2015, the majority of our revenues were derived from two wholesale distributors. The loss of the distributors could have a material negative effect on our financial condition.

During the year ended December 31, 2015, we derived 31.1% and 15.7% of our sales from two wholesale distributors. These two distributors purchase products from us on a purchase order basis on negotiated terms of payment. The distributors are under no obligation to continue to purchase our products. The loss of either of the distributors, a material reduction in their purchases or the cancellation of product orders or unexpected returns of unsold products could decrease our revenues and impede our future growth prospects. We do not have long-term purchase commitments with our distributors. We are actively seeking to expand our products’ distribution channels in order to reduce the impact the loss of any one distributor would have on our Company, however we can give no assurance that we will be successful in doing so.

If we breach any of our key license or supply agreements, we could lose exclusivity rights or the agreements could be terminated.

We have an international licensing agreement with kiWW for all cosmetic products for a term of eight years. These rights are important to our business, and any breach of the related agreements could result in a termination of the respective rights, which, in turn, would prevent us from marketing the affected products or developing the affected product candidates. Our agreements with kiWW require milestone and royalty payments, minimum revenue requirements or minimum annual royalty payments and other obligations. If we have insufficient demand for these products or otherwise fail to meet the minimum purchase requirements or any of the other requirements set forth in these agreements, we could lose the exclusive nature of our right to market products under the kiWW brand. Additionally, we are overdue in payments owed to kiWW. Should we not be able to cure this breach of our payment obligations under the agreement within a mutually agreeable timeframe, we face the possibility that the agreement could be terminated.

If we fail to comply with any of the requirements under our key license and supply agreements, we may lose exclusive rights under these agreements or they may be terminated in their entirety. Because at the time of this report, we remain overdue in payments owing to many of the counterparties to these agreements, there is a risk that such loss or termination is enhanced at present. In that event, others could obtain rights to sell products that compete directly with our products and our revenues and market share would correspondingly decrease. The loss of any rights under any of our license and supply agreements would adversely affect our ability to sell our products and adversely affect our revenues and results of operations

We rely on third parties to perform many necessary commercial services for our products, including services related to the distribution, storage, transportation and regulatory monitoring of our products. We rely on third parties to perform a variety of functions related to the sale and distribution of our cosmeceutical products. These services include distribution, logistics management, inventory storage and transportation, invoicing and collections, the key aspects of which are out of our direct control. If any third-party service provider fails to comply with applicable laws and regulations, fails to meet expected deadlines or otherwise does not carry out its contractual duties to us, our ability to deliver products to meet commercial demand would be significantly impaired. In addition, we may retain one or more third parties to perform various regulatory monitoring services for our products, including adverse event reporting, safety database management and other product maintenance services. If the quality or accuracy of the data maintained by these regulatory service providers is insufficient, our ability to continue to market our approved products could be jeopardized or we could be subject to regulatory sanctions.

If our competitors develop and market products faster than we do or if the products of our competitors are considered more desirable than our products, revenues of our existing or new products may be adversely affected.

The dermatology market in particular, is highly competitive and includes a number of established, large and mid-sized pharmaceutical and cosmeceutical companies, as well as smaller emerging companies and specialty pharmaceutical and cosmeceutical companies, whose activities are focused on our target markets and areas of expertise. We face and will continue to face, competition for our products and in the commercialization, development, licensing and discovery of our product candidates. This could negatively impact our ability to achieve significant market acceptance of our products and product candidates. Furthermore, new developments including the development of other drug technologies, delivery methods and improved formulations, occur in the pharmaceutical industry at a rapid pace. These developments may render our currently marketed products and product candidates or technologies obsolete or noncompetitive.

Compared to us, many of our competitors and potential competitors have substantially greater:

•

Capital resources;

	•		Research and development resources, including personnel and technology;
	•		Regulatory experience; Favorable brand name awareness;
	•		Clinical trial experience; and
	•		Manufacturing, distribution and sales and marketing experience.

As a result of these factors, our competitors may obtain regulatory approval of their products more rapidly than us. Our competitors may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates or technologies. Our competitors may also develop pharmaceutical and cosmeceutical products that are more effective and less costly than ours and may also be more successful than us in manufacturing and marketing their products.

Other competitors may invest significant amounts in achieving production economies of scale.

It is possible that our competitors may be able to reduce their cost of production so that they can aggressively price their products and secure a greater market share. Our competitors may also be able to attract and retain qualified personnel and to secure capital resources. Any of these events could adversely affect our ability to compete and our results of operations could suffer.

If we are unable to attract and retain key personnel, our business will suffer.

Our success depends on our continued ability to attract, retain and motivate highly qualified management, business development, sales and marketing, manufacturing, product development and other personnel. We may not be able to recruit and retain qualified personnel (particularly for senior sales and marketing and research and development positions) in the future due to intense competition for personnel among businesses like ours. The failure to do so could have a significant negative impact on our future product revenues and business results. Our success depends on a number of key management and technical personnel, including Ali Kharazmi, our President and Chief Executive Officer, Saeed Kharazmi, our Chairman of the Board, Acting Chief Financial Officer, and Sanjay Dhar, Ph.D, our Director of Research and Development. We are not aware of any present intention of these persons or any of our other executive officers to leave our company. In addition, we do not have “key person” insurance policies on any of our executive officers that would compensate us for the loss of their services. If we lose the services of one or more of these individuals, replacement could be difficult and may take an extended period of time and could impede significantly the achievement of our business objectives. This may have a material adverse effect on our results of operations and financial condition.

Our products and product candidates may cause undesirable side effects that could limit their use.

Skin irritation is a reported side effect of cosmeceutical products. Although these side effects generally are not severe, they may limit the use of our products, particularly if physicians or patients perceive the risks to outweigh the benefits or the side effects of competitive products to be less significant. If more severe side effects associated with any of our cosmeceutical products were to be reported or observed, we could be required to suspend our marketing of the products, conduct additional safety tests and potentially cease the sale of the products. In addition, we face the potential for product liability claims from any patients who experience side effects, whether or not any action is taken by a regulatory authority.

Undesirable side effects caused by our product candidates could interrupt, delay or halt our development programs, including clinical trials, and could result in the denial of any required regulatory approval by the FDA or other regulatory authorities.

We may face liability and indemnity claims that could result in unexpected costs and damage to our reputation.

Our business exposes us to potential liability risks that arise from the testing, manufacture and sale of our cosmeceutical products. Plaintiffs in the past have received substantial damage awards against pharmaceutical companies based upon claims for injuries allegedly caused by the use of their products. Although we currently maintain product liability insurance, there is no guarantee that any claims brought against us would be within our existing or future insurance policy coverage or limits. Any judgment against us that is in excess of our policy limits would have to be paid from our cash reserves, which would reduce our capital resources. Further, we may not have sufficient capital resources to pay a judgment, in which case our creditors could levy against our assets. Also, it may be necessary for us to recall products that do not meet approved specifications, which would result in adverse publicity, potentially significant costs in connection with the recall and a loss of revenues. Any product liability claim or series of claims brought against us could harm our business significantly, particularly if a claim resulted in adverse publicity or damage awards outside or in excess of our insurance policy limits.

Failure to adequately comply with information security policies or to safeguard against breaches of such policies could adversely affect our operations and could damage our business, reputation, financial position and results of operations.

In the process of making sales using consumer credit cards as a method of payment, we may handle and transfer such information as part of our business. These activities are subject to laws and regulations, as well as industry standards, in the United States and other jurisdictions in which our products and services are available. These requirements, which often differ materially and sometimes conflict among the many jurisdictions in which we operate, are designed to protect the privacy of consumers’ personal information and to prevent that information from being inappropriately used or disclosed. We maintain and review technical and operational safeguards designed to protect this information and generally require others with whom we work to do so as well. However, despite those safeguards, it is possible that hackers, employees acting contrary to our policies, third-party agents or others could improperly access relevant systems or improperly obtain or disclose data about our consumers, or that we may be determined not to be in compliance with applicable legal requirements and industry standards for data security, such as the Payment Card Industry guidelines. A breach or purported breach of relevant security policies that compromises consumer data or determination of non-compliance with applicable legal requirements or industry standards for data security could expose us to regulatory enforcement actions, card association or other monetary fines or sanctions, or contractual liabilities, limit our ability to provide our products and services, subject us to legal action and related costs and damage our business reputation, financial position, and results of operations.

Changes in economic conditions could materially affect our ability to maintain or increase sales.

The cosmeceutical industry depends on consumer discretionary spending. The United States in general or the specific markets in which we operate may suffer from depressed economic activity, recessionary economic cycles, higher fuel or energy costs, low consumer confidence, high levels of unemployment, reduced home values, increases in home foreclosures, investment losses, personal bankruptcies, reduced access to credit or other economic factors that may affect consumers discretionary spending. Economic conditions may remain volatile and may continue to depress consumer confidence and discretionary spending for the near term. Negative economic conditions might cause consumers to make changes to their discretionary spending behavior, including spending currently made on our cosmeceutical line of products. If such sales decrease, our profitability could decline as we spread fixed costs across a lower level of sales and this could materially adversely affect our business, financial condition or results of operations.

Our business is subject to intense competition and we may be unable to compete effectively against entrenched companies with larger resources and established channels of distribution.

Competition from other cosmeceutical businesses could impact sales and seriously harm our business, financial condition and results of operations. We strive to provide direct and indirect benefits to our distributors that are superior to, or competitive with, other cosmeceutical companies. If we are unable to provide our distributors with adequate benefits, or if any significant number of our distributors are not successful, we may be unable to maintain or renew our contractual relationships with distributors, causing our business, financial condition and results of operations to suffer.

The cosmeceutical industry in which we operate is highly competitive and increased competition could reduce our sales and profitability.

We compete in different markets within the cosmeceutical industry on the basis of the uniqueness of our product offerings, the quality of our products, customer service, price and distribution. Our markets are highly competitive. Our competitors vary in size and many may have greater financial and marketing resources than we do. If we cannot maintain quality and pricing that are comparable or superior to our competitors, we may not be able to grow our revenues and operating profits and we may lose market share. Competitive conditions could result in our experiencing reduced revenues, gross margins and operating results and could cause an investor in our Company to lose a substantial amount or all of its investment in our Company.

The loss of suppliers or shortages in ingredients could harm our business.

We acquire ingredients and products from third-party suppliers and manufacturers. A loss of any of these suppliers and any difficulties in finding or transitioning to alternative suppliers could harm our business. In addition, we obtain some of our products from sole suppliers that own or control the product formulations, ingredients, or other intellectual property rights associated with such products. In the event we are unable to renew these contracts, we may need to discontinue some products or develop substitute products, which could harm our revenue. In addition, if we experience supply shortages or regulatory impediments with respect to the raw materials and ingredients we use in our products, we may need to seek alternative supplies or suppliers and may experience difficulties in finding ingredients that are comparable in quality and price. Some of our products incorporate products that may have limited supplies. If demand exceeds forecasts, we may have difficulties in obtaining additional supplies to meet the excess demand. If we are unable to successfully respond to such issues, our business could be harmed.

FINANCIAL RISKS

Our financial statements have been prepared assuming that our Company will continue as a going concern and we will need to obtain additional funding if we are to continue operations.

The factors described elsewhere herein raise substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments that might result from this uncertainty. To date we have incurred significant cash losses that have materially impaired our liquidity and working capital. Additionally, during the last ninety days as we have sought to procure additional financing but were unsuccessful. We have been under severe liquidity restraints such that our CEO was required to personally guarantee borrowings may by our Company from our bank. This has resulted in the substantial increase in balances outstanding and owing to our suppliers that has put our relationships with them in jeopardy. We continue to attempt to procure the needed funding to maintain our operations. Should we be successful, we will need to quickly reverse the historical trend of our operations through generating significantly higher levels of revenue (at or about historical margins) and reducing our operating expenses. If we cannot generate the revenues and gross margin (while reducing operating expenses) at levels required to achieve profitability or obtain sufficient additional capital on acceptable terms, we will need to substantially revise our business plan or cease operations. Should that happen, an investor could suffer the loss of a significant portion or all of his investment in our Company.

We have a limited operating history and investors will have no ability to gauge market acceptance for our products or the ability of management to execute on our business plan.

We are an early-stage company with a limited operating history and limited revenues derived from our operations. Our operations to date have been primarily focused on our formation, the hiring of our management team, acquiring, licensing and developing our technology and products, building and expanding our sales force, marketing department and investor relations and commencing the commercial launch of our products.

It is difficult to predict future performance and our ability to maintain operations is dependent upon a number of factors over which we have limited control. As a result, it is difficult to predict our quarterly financial results and they are likely to fluctuate significantly. We are a relatively new company with a limited operating history and our sales prospects are uncertain. We also have relatively limited experience selling our products. Accordingly, we cannot predict with any certainty the timing or level of sales of our products in the future. If our quarterly sales or operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. In addition to the other factors discussed under these “Risk Factors,” specific factors that may cause fluctuations in our operating results include:

Demand and pricing for our products, including any change in wholesaler purchasing patterns for our products;

Physician and patient acceptance of our products;

Timing of new product offerings, acquisitions, licenses or other significant events by us, our partners or our competitors;

Regulatory approvals and legislative changes affecting our cosmeceutical products;

Any interruption in the manufacturing or distribution of our products, including events affecting our third-party suppliers and any failure to comply with manufacturing specifications;

Changes in treatment practices of physicians or other providers that currently recommend our products;

Significant product returns and rebates;

Implementation of new or revised accounting or tax rules or policies; and

The effect of competing technological and market developments.

Because we have a limited operating history, we are subject to all of the risks and uncertainties of a new business.

We only initiated the rollout of the NuGene Line in 2013. We are subject to all of the risks and uncertainties normally associated with an early stage business, including potential manufacturing issues, difficulties establishing our marketing and distribution operations, lack of name recognition, lack of adequate capital, difficulties hiring and retaining qualified employees and difficulties in complying with all applicable federal, state and local regulatory and administrative requirements. As an early stage company, we expect to incur operating losses until (if ever) we successfully release and market a line of products that will generate enough revenues and gross margin to become profitable or thereafter maintain profitability. There is no assurance that we will be able to validate and market products that will generate enough revenues for us to become profitable or thereafter maintain profitability. As a result, our Company cannot predict when, if ever, it might achieve profitability and cannot be certain that it will be able to sustain profitability, if achieved. Our lack of an operating history may make it difficult for you to evaluate our business prospects in connection with an investment in our securities.

We have had operating losses since the Merger and we expect to continue to incur net losses for the near term.

As of March 31, 2016, we had an accumulated deficit of approximately $7.6 million and we have reported a net loss of approximately $1.1 million for the three months ended March 31, 2016. Our working capital deficit as of March 31, 2016 amounted to approximately $1.2 million and was not adequate to sustain our operations. Unless our sales revenues increase significantly, we anticipate that we will continue to incur net losses in the near term and we may not be able to sustain operations at current levels.

We need to raise additional capital to continue our operations, which may not be available on commercially reasonable terms, or at all, and which materially may dilute your investment.

To attain profitability, we must increase our revenues and manage our product, operating and administrative expenses, as to which each of which we can give no assurance. Because we have been to date unable to generate sufficient revenues to pay our expenses and our existing sources of cash and cash flows are otherwise insufficient to fund our activities, we currently must raise additional funds to continue our operations and to manage our current short-term debt load. Further, recent efforts to raise additional capital have been unsuccessful. We do not have any arrangements in place for additional funds and no assurance can be given that those funds will become available on favorable terms, or at all. Furthermore, if we issue equity or debt securities to raise additional funds, our existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders. If we are unsuccessful in obtaining additional funds on commercially reasonable terms or at all, and thereafter in achieving profitability, we may be required to curtail significantly or cease our operations, which could result in the loss of all of your investment in our stock.

Should we be able to obtain additional financing and thereafter be successful in growing our revenues according to our operating plans, we may not be able to manage our growth effectively, which could adversely affect our operations and financial performance.

The ability to manage and operate our business as we execute our growth strategy will require further substantial capital and effective planning. Additionally, we have not been able to maintain adequate levels of capital to fund existing operations. Significant rapid growth on top of our current operations could greatly strain our internal resources, leading to a much lower quality of customer service, reporting problems and delays in meeting important deadlines resulting in substantial loss of market share and other problems that could adversely affect our financial performance. Our efforts to grow could place a significant strain on our personnel, management systems, infrastructure, liquidity and other resources. If we do not manage our growth effectively, our operations could be adversely affected, resulting in slower, no or negative growth, critical shortages of cash and a failure to achieve or sustain profitability.

We will not pay dividends for the foreseeable future, and we may never pay dividends and, consequently, the only opportunity for investors to achieve a return on their investment is if a trading market develops and investors are able to sell their shares for a profit or if our business is sold at a price that enables investors to recognize a profit.

We currently intend to retain future earnings (if any) to support the development and expansion of our business and will not pay cash dividends for the foreseeable future. Our payment of any future dividends will be at the discretion of our Board of Directors after taking into account various factors, including but not limited to our financial condition, operating results, cash needs, growth plans and the terms of any credit agreements that we may be a party to at the time. In addition, our ability to pay dividends on our common stock may be limited by state law. Accordingly, we cannot assure investors any return on their investment, other than in connection with a sale of their shares or a sale of our business. The trading market for our shares has been volatile and holders of our securities (which are highly speculative) may experience fluctuations and losses.

Significant differences between actual and estimated demand for our products could adversely affect us.

If we overestimate demand, we may be required to write off inventories and increase our reserves for product returns or liabilities to customers in future periods. If we underestimate demand, we may not have sufficient inventory of products to ship to our customers. Our cosmeceutical products have expiration dates that generally range from 24 to 36 months from the date of manufacture. Judgment is required in estimating these reserves. The actual amounts could be materially different from our estimates, and differences will need to be accounted for in the period in which they become known. If we determine that the actual amounts exceed our reserve amounts, we will record a charge to earnings to approximate the difference. A material reduction in earnings resulting from a charge could have a material adverse effect on our net income, results of operations and financial condition.

We currently need to raise additional funds to continue our operations and still pursue our growth strategy and if we are unable to raise that capital, we will need to curtail or even to cease operations.

Our current cash and cash equivalents are insufficient to fund our operations through the end of our second quarter in 2016. We need to raise additional funds to finance our operations and to fund product development programs, sales and marketing initiatives for our current products. Factors affecting our product development expenses include, but are not limited to:

The number of our products in early-stage development;

Our licensing or other partnership activities, including the timing and amount of related development funding, licensee fees or milestone payments;

The number and outcome of clinical trials conducted by us and/or our collaborators; and

Our future levels of revenue.

We hope to satisfy our future cash needs through private equity offerings, debt financings or collaboration, licensing and other similar arrangements. Additional funding may not be available to us on acceptable terms, or at all, and without that funding we may not be able to continue operations. To the extent that we raise additional capital by issuing equity securities, our stockholders’ ownership will be diluted and possibly substantially.

If we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish potentially valuable rights to our current products, potential products or proprietary technologies, or grant licenses on terms that are not favorable to us.

If adequate funds are not available, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and we may be required to delay, significantly curtail or eliminate the sales of one or more of our current products and/or the development of one or more of our potential products.

CORPORATE AND OTHER RISKS

Our Company is delinquent with respect to the payroll taxes required to be deposited.

We are delinquent with respect to the deposit of required payroll tax withholdings and related employer taxes. As of the date of this report, the deficiencies approximate $70,000, not including any penalties and interest. In addition to the pressing capital need associated with the satisfaction of the deposit deficiencies, should the government entities to whom we are in arrears take administrative or criminal action against our Company, not only might our operations be severely disrupted, individual officers or members of our Board of Directors may be personally liable for any assessments made. A government entity could potentially shut down our Company until such time as its delinquencies were brought current. Such a shutdown could effectively push our Company into bankruptcy. Such governmental actions could cause our operations to cease and an investor would lose all his or her investment in our Company.

Our executive officers, directors and principal stockholders beneficially own or control a substantial portion of our outstanding common stock, which may limit the ability of our stockholders, whether acting alone or together, to propose or direct the management on the overall direction of our Company.

Additionally, this concentration of ownership could discourage or prevent a potential takeover of our Company that might otherwise result in an investor receiving a premium over the market price for his shares. A substantial portion of our outstanding shares of common stock is beneficially owned and controlled by a group of insiders, including our officers and directors. Accordingly, our principal stockholders together with our directors, Chief Executive Officer and insider shareholders would have the power to control the election of our directors and the approval of actions for which the approval of our stockholders is required. If you acquire shares of our common stock, you may have no effective voice in the management of our Company. Such concentrated control of our Company may adversely affect the price of our common stock. Our principal stockholders may be able to control matters requiring approval by our stockholders, including the election of directors, mergers or other business combinations. Such concentrated control may also make it difficult for our stockholders to receive a premium for their shares of our common stock in the event we merge with a third party or enter into different transactions that require stockholder approval. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock.

Our Chief Executive Officer and our Chief Financial Officer have limited experience in these roles in a public company.

To serve in the roles of officer and/or director for a public company, an individual needs to be aware of responsibilities in addition to those shouldered by the leader of a private company. Among such additional responsibilities, a senior executive officer must be able to communicate fairly and effectively with the stakeholders of a public company, be aware of the controls required to be maintained by a public company and act in accordance with the legal requirements incumbent upon such senior executives and directors. Neither of our officers (who serve as our only directors), have such experience, the absence of which could increase our exposure to untimely compliance with applicable regulation that could result in possible added liability and cost to the material detriment of our operations and financial interests. Our CFO is a medical doctor by training and has assumed the title and responsibility of a chief financial officer but has not had any prior experience in the traditional services to be rendered but has rather relied on staff and consultants in his acting in this capacity.

We do not have an Audit Committee and we have no independent persons serving on our Board of Directors.

As of the date of this Annual Report, we do not have an independent Audit Committee. An Audit Committee qualitatively enhances a company’s internal controls over financial reporting. Among its functions, independent Audit Committees review the financial reporting, internal controls safeguarding Company assets, interact with auditors, may oversee material financial decisions and provide a sounding board for individuals who believe that there are irregularities in a Company’s accounting policies and procedures. Our Board of Directors consists of our CEO and our CFO and no other persons currently serve on our board. With our lack of an independent Audit Committee and other outside board members at this time, we run a greater risk that a significant error or irregularity could occur that could be materially damaging to our shareholders.

Issuances of our Series A Preferred Stock or other authorized shares of preferred stock may make it more difficult for a third party to effect a change-of-control.

Our articles of incorporation authorize the Board of Directors to issue up to 25,000,000 shares of "blank check" preferred stock. The preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by the Board of Directors without further action by the stockholders. These terms may include preferences as to dividends and liquidation, conversion rights, redemption rights and sinking fund provisions. In connection with the Merger, we issued (in addition to common stock) 1,917,720 shares of Series A Preferred Stock to NuGene's two founders. The Series A Preferred Stock is initially convertible into common stock at a ratio of one to one, has the right to elect a majority of the board of directors and has in connection with any other vote of shareholders three votes for every vote available to the common stock. These outstanding shares of Series A Preferred Stock diminish and any future issuances of other series of preferred stock could further diminish the rights of holders of our common stock, and therefore could reduce the value of such common stock. In addition, the Series A Preferred Stock could be used to restrict our ability to merge with, or sell assets to, a third party. The Series A Preferred Stock specifically, and the ability of the Board of Directors generally, to issue preferred stock make it more difficult, and could delay, discourage, prevent or make it more costly to acquire or effect a change-in-control, which in turn could prevent our stockholders from recognizing a gain in the event that a favorable offer is extended and could materially and negatively affect the market price of our common stock. The summary description of the Series A Preferred Stock contained in this Annual Report is qualified in its entirety by reference to the Certificate of Designations filed with Secretary of State of Nevada on December 24, 2014 and included in our Current Report on Form 8-K filed with the SEC on January 6, 2015.

We have incurred significantly increased costs as a result of being a public company.

In reviewing the past operations of NuGene and future prospects, investors should recognize that we have incurred and will continue to incur significant legal, accounting and other expenses that NuGene did not incur as a private company, particularly if we are no longer characterized as an "emerging growth company" as defined under the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). In addition, new and changing laws, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall Street Reform and Consumer Protection Act and the rules and regulations promulgated and to be promulgated thereunder, as well as under the Sarbanes-Oxley Act of 2002, as amended (the "Sarbanes-Oxley Act"), and the JOBS Act, have created uncertainty for public companies and increased costs and time that boards of directors and management must devote to complying with these rules and regulations. The Sarbanes-Oxley Act and related rules of the U.S. Securities and Exchange Commission, or SEC, and the Nasdaq markets regulate corporate governance practices of public companies. Compliance with these rules and regulations has and will continue to increase our legal and financial compliance costs and lead to a diversion of management time and attention from revenue generating activities. For example, we may be required to adopt new internal controls and disclosure controls and procedures as well as incurring additional expenses associated with our SEC reporting requirements.

For as long as we remain an "emerging growth company" as defined in the JOBS Act, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not "emerging growth companies."

These exceptions provide for, but are not limited to, relief from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, less extensive disclosure obligations regarding executive compensation in our periodic reports and proxy statements, exemptions from the requirements to hold a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved and an extended transition period for complying with new or revised accounting standards. We may take advantage of these reporting exemptions until we are no longer an "emerging growth company." We may remain an "emerging growth company" for up to five years. To the extent we use exemptions from various reporting requirements under the JOBS Act, we may be unable to realize our anticipated cost savings from those exemptions.

Pursuant to the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act for so long as we are characterized as an "emerging growth company." Section 404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting, starting with the second annual report that we file with the SEC as a public company, and generally requires in the same report a report by our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. However, under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act until we are no longer an "emerging growth company."

CAPITAL MARKET RISKS

The recent public market for our shares has been and may continue to be volatile. This volatility may affect the ability of our investors to sell their shares as well as the price at which they sell their shares.

The market price for our shares may be significantly affected by factors such as variations in the volume of trading activity, quarterly and yearly operating results, general trends in the markets we serve, press releases announcing developments and changes in state or federal regulations affecting us and our industry. Furthermore, in recent years the stock market has experienced extreme price and volume fluctuations that are unrelated or disproportionate to the operating performance of the affected companies. Such broad market fluctuations may adversely affect the market price of our common stock.

The application of the “penny stock” rules to our common stock could limit the trading and liquidity of the common stock, adversely affect the market price of our common stock and increase your transaction costs to sell those shares.

As long as the trading price of our common stock is below $5 per share, the open-market trading of our common stock will be subject to the “penny stock” rules, unless we otherwise qualify for an exemption from the “penny stock” definition. The “penny stock” rules impose additional sales practice requirements on certain broker-dealers who sell securities to persons other than established customers and accredited investors (generally those with assets, excluding principal residence, in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse). These regulations, if they apply, require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the associated risks. Under these regulations, certain brokers who recommend such securities to persons other than established customers or certain accredited investors must make a special written suitability determination regarding such a purchaser and receive such purchaser’s written agreement to a transaction prior to sale. These regulations may have the effect of limiting the trading activity of our common stock, reducing the liquidity of an investment in our common stock and increasing the transaction costs for sales and purchases of our common stock as compared to other securities. The stock market in general and the market prices for penny stock companies in particular, have experienced volatility that often has been unrelated to the operating performance of such companies. These broad market and industry fluctuations may adversely affect the price of our stock, regardless of our operating performance. Stockholders should be aware that, according to SEC Release No. 34-29093, the market for penny stocks has suffered in recent years from patterns of fraud and abuse. Such patterns include 1) control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer; 2) manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; 3) boiler room practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales persons; 4) excessive and undisclosed bid-ask differential and markups by selling broker-dealers; and 5) the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the resulting inevitable collapse of those prices and with consequent investor losses. The occurrence of these patterns or practices could increase the volatility of our share price.

We may not be able to attract the attention of brokerage firms, which could have a material adverse impact on the market value of our common stock.

Security analysts of brokerage firms are unlikely to provide coverage of our common stock since there is no incentive to brokerage firms to recommend the purchase of our common stock. The absence of such coverage limits the likelihood that an active market will develop or be maintained for our common stock. It will also likely make it more difficult to attract new investors at times when we require additional capital.

Future sales of our equity securities could put downward selling pressure on our securities, and adversely affect the stock price.

There is a risk that this downward pressure may make it impossible for an investor to sell his or her securities at any reasonable price, if at all. Future sales of substantial amounts of our equity securities in the public market, or the perception that such sales could occur, could put downward selling pressure on our securities, and adversely affect the market price of our common stock.

Risks Related to Regulatory Matters

While we believe that that our principal cosmeceutical products and product candidates do not require FDA approval as new drugs, the FDA could disagree and we may be required to conduct clinical trials to establish efficacy and safety or cease to market these products.

Our cosmeceutical products are marketed without FDA approval on the basis that they are generally recognized as safe and effective for their intended use and thus do not require new drug approval. The FDA has not challenged this position. The FDA may at any time disagree with our position for a variety of reasons, including new information about the particular product or its active ingredients, how the product is promoted, if another company obtains FDA approval for a prescription drug with the same active ingredient, or based on a change of FDA regulatory policy. This could require us to seek new drug approval for these products to remain on the market or to withdraw a product until required clinical trials are performed and new drug approval is obtained.

If the active ingredients of the products are finally determined by the FDA not to be generally recognized as safe and effective for OTC use, the FDA may seek to apply those findings to prescription products as well, leading to potential objections to the continued marketing of the products or a demand that marketing continue only on the basis of a new drug approval. Either of these outcomes could affect the way our products are marketed or our ability to market them at all. Further, the FDA could decide that growth factors derived from human adipose stem cells do not come within this policy and thus must seek new drug approval to remain on the market or must be withdrawn until approval is obtained.

Our pharmaceutical products under development may not be approved by the FDA or foreign regulatory authorities, and any failure or delay associated with our product development and clinical trials or obtaining regulatory approval of these products would increase our product development costs and time to market. We face substantial risks of failure inherent in developing pharmaceutical products. The pharmaceutical industry is subject to stringent regulation by many different agencies at the federal, state and international levels. Our pharmaceutical products must satisfy rigorous standards of safety and efficacy before the FDA approves them, and before any foreign regulatory authorities approve them for commercial use in any countries outside the U.S. where we decide to market them. Even if a regulatory filing is accepted, the FDA or foreign regulatory authorities may request additional information from us, including data from additional clinical trials, and, ultimately, may not grant marketing approval for some of our products or may grant approval only under conditions that are less commercially attractive than anticipated. To the extent that these products do not perform successfully in our planned pivotal clinical trials, we may need to develop alternative candidates. Product development is generally a long, expensive and uncertain process. Successful development of our new pharmaceutical product formulations, including our burn cream will depend on many factors, including:

Our ability to select key components, establish a stable formulation and optimize characteristics;

Our ability to develop a formulation that demonstrates our intended safety and efficacy profile; and

Our ability to transfer from an early-stage company to commercial-scale operations and the costs associated with commercial manufacturing.

If we are unable to develop suitable clinical formulations of our pharmaceutical products or are significantly delayed in doing so, our ability to commercialize these products will be adversely affected. Once we have manufactured a formulation that we believe is suitable for pivotal clinical testing, we will need to complete our clinical testing, and failure can occur at any stage of testing. These clinical tests must comply with FDA and other applicable regulations. We may suffer significant setbacks in advanced clinical trials, even after showing promising results in earlier trials. The results of later clinical trials may not replicate the results of prior clinical trials. Based on results at any stage of clinical trials, we may decide to discontinue development of a product candidate. We, or the FDA, may suspend clinical trials at any time if the patients participating in the trials are exposed to unacceptable health risks or if the FDA finds deficiencies in our applications to conduct the clinical trials or in the conduct of our trials. Moreover, not all products in clinical testing will receive timely, or any, regulatory approval. Even if clinical trials are completed as planned, their results may not support our assumptions or our product claims. The clinical process may fail to demonstrate that our products are safe for humans or effective for intended uses. In addition, these failures could cause us to abandon a product entirely. If we fail to take any current or future product from the development stage to market, we will have incurred significant expenses without the possibility of generating revenues, and our business will be adversely affected.

We will be subject to ongoing regulatory review of products currently under development that may be marketed in the future.

Any pharmaceutical products under development will be subject to extensive regulation. These regulations will impact many aspects of our operations, including the manufacture, labeling, packaging, adverse event reporting, storage, advertising, promotion and record keeping related to the products. The FDA also may require post-marketing testing and surveillance to monitor the effects of approved products or place conditions on any approvals that could restrict the commercial applications of these products. In addition, the subsequent discovery of previously unknown problems with a product may result in restrictions on the product, including withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, injunctions against their distribution, disgorgement of money, operating restrictions and criminal prosecution.

In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes and false claims statutes. Violations of the federal anti-kickback statute are punishable by imprisonment, criminal fines, civil monetary penalties and exclusion from participation in federal healthcare programs. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions under the federal anti-kickback statute, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing, arranging for or recommending prescription or purchase may be subject to scrutiny if they do not qualify for a statutory exemption or safe harbor. Federal false claims laws prohibit any person from knowingly making, or causing to be made, a false claim to the federal government, or knowingly making, or causing to be made a false statement to have a false claim paid. The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Sanctions under these federal and state laws may include civil monetary penalties, exclusion of a manufacturer’s products from reimbursement under government programs, criminal fines and imprisonment.

In addition, as part of the sales and marketing process, pharmaceutical companies frequently provide samples of approved drugs to physicians. This practice is overseen by the FDA and other governmental authorities under regulations that include, in particular, requirements concerning record keeping and control procedures. Any failure to comply with these regulations may result in significant criminal and civil penalties as well as damage to our credibility in the marketplace. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of these laws, which could have a material adverse effect on our business, financial condition and results of operations.

The regulatory status of our cosmeceutical products could change, and we may be required to conduct clinical trials to establish efficacy and safety or cease to market these products.

The Federal Food, Drug, and Cosmetic Act does not recognize “cosmeceuticals” as a category of products. We use the term “cosmeceuticals” as a marketing term to describe our non-prescription, cosmetic products. The FDA does not have a premarket approval system for cosmetic products outside of new color additive, and we believe we are permitted to market our cosmeceutical products and have them manufactured without submitting safety or efficacy data to the FDA. However, the FDA may in the future determine to regulate what we term as cosmeceuticals or the ingredients included in our cosmeceuticals as drugs or biologics, rather than cosmetics. If any of our products are deemed to be drugs or biologics, rather than cosmetics, we would be required to conduct clinical trials to demonstrate the safety and efficacy of our cosmeceutical products in order to continue to market and sell them. In such event, we may not have sufficient resources to conduct any required clinical trials and we may not be able to establish sufficient efficacy or safety data to resume the sale of our cosmeceutical products. Any inquiries by the FDA or any foreign regulatory authorities into the regulatory status of our cosmeceutical products and any related interruption in the marketing and sale of our cosmeceutical products could severely damage our brands and image in the marketplace, including our relationships with physicians and their patients.

If our manufacturers do not comply with U.S. and federal regulations, our supply of product could be disrupted or terminated.

Our manufacturers must comply with U.S. regulations and corresponding foreign standards, including the FDA’s current Good Manufacturing Practice regulations for drug manufacturing and processing, or cGMPs, applicable to the manufacturing processes related to ingredients sold to us for use in our products, and their facilities must be inspected and approved by the FDA and other regulatory agencies as part of their business. We will have limited control over the FDA compliance of our third-party manufacturers. If any of our manufacturers fail to meet or are found to be non-compliant with the cGMPs or any other FDA requirements or similar regulatory requirements outside of the U.S., obtaining the required regulatory approvals, including from the FDA, to use alternative suppliers may be a lengthy and uncertain process. A lengthy interruption in the manufacturing of one or more of our products as a result of non-compliance could adversely affect our product inventories and supply of products available for sale which could reduce our sales, margins and market share, as well as harm our overall business and financial results. Additionally, the Federal Drug and Cosmetic Act (“FDCA”) may hold labelers/specification developers (brands selling a product) criminally and civilly liable for the violations, acts, and omission of their manufacturers.

Under the FDCA, cosmetics (which we refer to as cosmeceuticals) are defined as articles applied to the human body to cleanse, beautify or alter the appearance. The manufacturing of cosmetics is subject to the misbranding and adulteration sections of the FDCA applicable to cosmetics. Cosmetics are not subject to premarket approval by the FDA but the product and ingredients must be tested to assure safety. If the product or ingredients are not tested for safety, a specific warning is required. The FDA monitors compliance of cosmetic products through random inspections of cosmetic manufacturers and distributors. The FDA utilizes an “intended use” doctrine to determine whether a product is a drug or cosmetic by the labeling claims made for the product. If a cosmetic product is intended for a disease condition or to affect the structure or any function of the human body, the FDA will regulate the product as a drug rather than as a cosmetic. The product will then be subject to all drug requirements under the FDCA. The labeling of cosmetic products is subject to the requirements of the FDCA, the Fair Packaging and Labeling Act and other FDA regulations.

We have only limited experience in regulatory affairs, which may affect our ability or the time we require to obtain necessary regulatory approvals. We have only limited experience in regulatory affairs, including the preparation and filing of applications to gain the regulatory approvals necessary for pharmaceutical product candidates. Moreover, some of the products that are likely to result from our product development, licensing and acquisition programs may be based on new technologies that have not been extensively tested in humans. As a result, we may experience a longer regulatory process in connection with obtaining regulatory approvals for any products that we develop, license or acquire.

If we move forward with production of an FDA regulated product, then our operations could be harmed if we are found not to be in compliance with Good Manufacturing Practices.

In the United States, FDA regulations on Good Manufacturing Practices and Adverse Event Reporting requirements require us and our vendors to maintain good manufacturing processes, including stringent vendor qualifications, ingredient identification, manufacturing controls and record keeping. The ingredient identification requirement, which requires us to confirm the levels, identity and potency of ingredients listed on our product labels within a narrow range, is particularly burdensome and difficult for us with respect to products that contain many different ingredients. We are also required to report serious adverse events associated with consumer use of our products. Our operations could be harmed if regulatory authorities make determinations that we, or our vendors, are not in compliance with these regulations or public reporting of adverse events harms our reputation for quality and safety. A finding of noncompliance may result in administrative warnings, penalties or actions impacting our ability to continue selling certain products. In addition, compliance with these regulations has increased and may further increase the cost of manufacturing certain of our products as we work with our vendors to assure they are qualified and in compliance.

RISKS RELATED TO OUR INTELLECTUAL PROPERTY

If we are unable to obtain and maintain protection for our intellectual property, the value of our technology and products may be adversely affected, which would materially affect our business.

Patents. Our commercial success will continue to depend in part on the patent rights we plan to obtain related to future products we may market. Our success also depends on our and our licensors’, collaborators’, and suppliers’ ability to maintain these patent rights against third-party challenges to their validity, scope or enforceability of these patent rights.

Our patent position (and those of our licensors, collaborators and suppliers) is subject to the same uncertainty as other pharmaceutical and consumer product companies. Our patents and patent applications (as well as those of our licensors, collaborators and suppliers) may not protect our technologies and products because, among other things, our pending applications may not result in issued patents; we may develop additional proprietary technologies that are not patentable; patents issued to us may not provide a basis for future commercially viable products; and patents issued to us may not provide us with any competitive advantage, or may be challenged, circumvented, invalidated or rendered unenforceable by third parties. For example, the USPTO or the courts may deny, narrow or invalidate patent claims, particularly those that concern biotechnology and pharmaceutical inventions. Inventors or third parties of whom we are unaware, may challenge the ownership of patents and applications we own, license or benefit from through supply agreements with our collaborators and suppliers. We, our licensors, collaborators and suppliers may not be successful in securing or maintaining proprietary or patent protection for our products, and protection that is secured may be challenged and possibly lost.

Our competitors may develop products similar to ours using methods and technologies that are beyond the scope of our intellectual property rights.

Composition of matter patents on active pharmaceutical ingredients may provide protection for competing products without regard to formulation or other type of limitation.

Our primary patent protection strategy consists of obtaining patents for the formulation and methods of manufacturing our products and product candidates when appropriate, in addition to our pending composition patent claims. Our competitors or other third parties, including generic drug companies, may challenge the scope, validity or enforceability of our patent claims. As a result, these patents may be narrowed in scope, invalidated or deemed unenforceable and may fail to provide us with any market exclusivity or competitive advantage even after significant investment in efforts to obtain and maintain a meaningful competitive patent position. Additionally, rights we issue to U.S. and foreign patents that we own or license will be limited to the terms of the patents in the respective countries where the patents issued.

We also may not be able to protect our intellectual property rights against third-party infringement, which may be difficult to detect, especially for infringement of patent claims for methods of manufacturing. If we become involved in any dispute regarding our intellectual property rights, regardless of whether we prevail, we could be required to engage in costly, distracting and time-consuming litigation that could harm our business. As a result of general uncertainties in the patent prosecution process, we cannot be sure that any additional patents will ever be issued. Issued patents generally require the payment of maintenance or similar fees. Failure to make these payments could result in the unenforceability of patents not maintained.

Trade Secrets and Proprietary Know-how. We, our licensors, collaborators and suppliers also rely upon trade secrets, proprietary know-how and other technological innovation, particularly when patent protection is not appropriate or available. However trade secrets are difficult to protect, and we have limited control over the protection of trade secrets used by our licensors, collaborators and suppliers. Although we attempt to protect our trade secrets by requiring our employees, consultants, advisors and current and prospective business partners to enter into confidentiality agreements prohibiting them from disclosing or taking our proprietary information and technology, these agreements may not provide meaningful protection for our trade secrets and proprietary know-how. If our employees or consultants breach these agreements, we may not have adequate remedies for any of these breaches. Further, third parties that are not parties to confidentiality agreements may obtain access to our trade secrets or know-how. Others may independently develop similar or equivalent trade secrets or know-how. If our confidential or proprietary information is divulged to third parties, including our competitors, our competitive position in the marketplace will be harmed and our ability to successfully penetrate our target markets could be severely compromised.

Trademarks. Our trademarks will continue to be important to our success and competitive position. We have received U.S. trademark registration for our corporate name, NuGene^®, and own or have rights to use our product and component names. We also have license regarding the use of Kathy Ireland^®who acts as our brand ambassador. We also will need to pursue trademark registration for any new trademarks that we select. We may not be able to secure any of our trademark registrations with the PTO or comparable foreign authorities. If we do not adequately protect our rights in our various trademarks from infringement (and we are involved in two separate ongoing disputes with respect to trademarks), any goodwill that has been developed in those marks would be lost or impaired. We could also be forced to cease using any of our trademarks that are found to infringe upon or otherwise violate the trademark or service mark rights of another company, and, as a result, we could lose all the goodwill that has been developed in those marks and could be liable for damages caused by any infringement or violation.

Our ability to market our products may become subject to the intellectual property rights of third parties, and we may have to engage in costly litigation to enforce or defend challenges to our intellectual property by third parties, which may harm our results of operations, financial condition and cash flow.

Our commercial success will continue to depend in part on our ability, as well as the ability of our collaborators and suppliers, to make, use and sell our products without infringing the patents or proprietary rights of third parties. Our competitors, many of which have substantially greater resources than we have and have made significant investments in competing technologies or products, may seek to apply for and obtain patents that will prevent, limit or interfere with our ability to make, use and sell products either in the U.S. or international markets. We may not be aware of all of the patents and other intellectual property rights of others potentially adverse to our interests that may be owned by third parties.

Our third-party suppliers may also be notified of alleged infringement, and potentially be sued for infringement of patents or other proprietary rights. We may have limited control or involvement over the defense of these claims, and these third parties could be subject to injunctions and temporary or permanent exclusionary orders in the U.S. or in the countries in which they are based. Because of the uncertainty inherent in any patent or other litigation involving proprietary rights, we (or our licensors, collaborators or suppliers) may not be successful in defending claims of intellectual property infringement by third parties. This could likely have a material adverse effect on our results of operations. Regardless of the outcome of any litigation, defending the litigation may be expensive, time-consuming and distracting to management.

If we or our third-party licensors and suppliers are unsuccessful in any challenge to our rights to market and sell our products, we may (among other things) be required to:

•

pay actual damages, royalties, lost profits and/or increased damages and the third party’s attorneys’ fees, which may be substantial;

•

cease the development, manufacture, use and/or sale of products that use the intellectual property in question through a court-imposed sanction called an injunction;

•

expend significant resources to modify or redesign our products, manufacturing processes or other technology so that it does not infringe others’ intellectual property rights or to develop or acquire non-infringing technology (which may not be possible); or

•

obtain licenses to the disputed rights that could require us to pay substantial upfront fees and future royalty payments and may not be available to us on acceptable terms, if at all, or to cease marketing the challenged products.

Ultimately, we could be prevented from selling a product, commercializing a product candidate, or otherwise forced to cease some aspect of our business operations as a result of any intellectual property litigation. Even if we (or our collaborators and suppliers) are successful in defending an infringement claim, the expense, time delay, and burden on management of litigation and negative publicity could have a material adverse effect on our business.

We may be subject to claims that we, or our employees, have inadvertently or otherwise used or disclosed alleged trade secrets or other proprietary information of our employees' former employers.

We employ individuals who were previously employed at other personal care product or nutritional supplement companies, including our competitors or potential competitors. To the extent that our employees are involved in research areas that are similar to those in which they were involved with their former employers, we may be subject to claims that such employees have inadvertently or otherwise used or disclosed the alleged trade secrets or other proprietary information of the former employers. Litigation may be necessary to defend against such claims.

ITEM 2. UNREGISTERD SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

We believe that the above issuances are exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

2.1		Agreement and Plan of Merger dated December 26, 2014, among our Company, NG Acquisition, Inc. and NuGene Inc. ⁽¹⁾
3.1		Certificate of Amendment of Articles of Incorporation of the Registrant, (increase of authorized, new class of preferred). ⁽¹⁾
3.2		Certificate of Amendment of Articles of Incorporation of the Registrant, name change.⁽¹⁾
4.1		Certificate of Designation of Series A Preferred Stock. ⁽¹⁾
10.1		Form of Lock Up Agreement-NuGene Shareholders⁽¹⁾
10.2		Form of Lock Up/Leak Out Agreement— Stock Placement Investors⁽¹⁾
10.3		License Agreement between the Registrant and kathy ireland Worldwide, Inc. ⁽¹⁾
10.4		Sublease Agreement between the Registrant and Advanced Surgical Partners, Inc. ⁽¹⁾
10.5		Form of Convertible Promissory Note. ⁽¹⁾
10.6		Business Transfer and Indemnity Agreement, dated December 29, 2014, between the Registrant and Dena Kurland. ⁽¹⁾
10.7		Form of Stock Purchase Agreement (April 2015)⁽³⁾
10.8		Offer Letter to join Board of Directors between NuGene International, Inc. and Donna Queen⁽⁴⁾
21.1		List of subsidiaries of the Registrant. ⁽²⁾
31.1		Certification of Principal Executive Officer of NuGene International, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *
31.2		Certification of Principal Financial and Accounting Officer of NuGene International, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1		Certifications of Principal Executive Officer and Principal Financial and Accounting Officer of NuGene International, Inc. pursuant to Rule 13a-14(b) under the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *
101.INS		XBRL Instance Document.
101.SCH		XBRL Taxonomy Extension Schema Document.
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB		XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.

Included herein.

⁽¹⁾

Incorporated by reference to the registrant’s filing on a Form 8-K, filed with the Securities and Exchange Commission on January 6, 2015.

⁽²⁾

Incorporated by reference to the registrant’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission on March 30, 2015.

⁽³⁾

Incorporated by reference to the registrant’s Quarterly Report on Form 10-Q for the period ended March 31, 2015, filed with the Securities and Exchange Commission on May 15, 2015.

⁽⁴⁾

Incorporated by reference to the registrant’s filing on a Form 8-K, filed with the Securities and Exchange Commission on May 29, 2015.

Signatures

In accordance with Section 13 or 15(d) of the Exchange Act, our Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NuGene International, Inc. (Registrant)

Date: May 23, 2016	By:	/s/ ALI KHARAZMI
		Ali Kharazmi
		Chief Executive Officer

Date: May 23, 2016	By:	/s/ SAEED KHARAZMI
		Saeed Kharazmi, M.D.
		Acting Chief Financial Officer

EX-31.1 2 s103253_ex31-1.htm EXHIBIT 31-1

EXHIBIT 31.1

CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002 CERTIFICATION

I, Ali Kharazmi, certify that:

I have reviewed this Quarterly Report on Form 10-Q of NuGene International, Inc. for the period ended March 31, 2016;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 23, 2016
/s/ Ali Kharazmi
Name: Ali Kharazmi
Its: Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 s103253_ex31-2.htm EXHIBIT 31-2

EXHIBIT 31.2

CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002 CERTIFICATION

I, Saeed Kharazmi, certify that:

I have reviewed this Quarterly Report on Form 10-Q of NuGene International, Inc. for the period ended March 31, 2016;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 23, 2016
/s/ Saeed Kharazmi
Name: Saeed Kharazmi, M.D.
Its: Acting Chief Financial Officer (Principal Financial Officer)

EX-32.1 4 s103253_ex32-1.htm EXHIBIT 32-1

EXHIBIT 32.1

Certification
Pursuant To Section 906 of the Sarbanes-Oxley Act Of 2002

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of NuGene International, Inc. (the ''Company’’), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the period ended March 31, 2016 (the ''Form 10-Q’’) of our Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of our Company.

	Dated: May 23, 2016		/s/ ALI KHARAZMI
			Ali Kharazmi Chief Executive Officer (Principal Executive Officer)

	Dated: May 23, 2016		/s/ SAEED Kharazmi
			Saeed Kharazmi, M.D. Acting Chief Financial Officer (Principal Financial Officer)

A signed original of this written statement required by Section 906 has been provided to our Company and will be retained by our Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 5 nugn-20160331.xml XBRL INSTANCE FILE 0001593549 2015-12-31 0001593549 2016-03-31 0001593549 2016-01-01 2016-03-31 0001593549 NUGN:AspMember 2015-12-31 0001593549 us-gaap:LeaseholdImprovementsMember 2015-12-31 0001593549 us-gaap:LeaseholdImprovementsMember 2016-03-31 0001593549 us-gaap:EquipmentMember 2015-12-31 0001593549 us-gaap:EquipmentMember 2016-03-31 0001593549 us-gaap:ComputerSoftwareIntangibleAssetMember 2015-12-31 0001593549 us-gaap:ComputerSoftwareIntangibleAssetMember 2016-03-31 0001593549 2015-01-01 2015-03-31 0001593549 NUGN:SingleWholesaleDistributorMember us-gaap:SalesRevenueNetMember 2015-01-01 2015-03-31 0001593549 NUGN:KathyIrelandWorldwideMember 2016-01-01 2016-03-31 0001593549 us-gaap:MinimumMember 2016-01-01 2016-03-31 0001593549 us-gaap:MaximumMember 2016-01-01 2016-03-31 0001593549 NUGN:ExercisePriceOneMember us-gaap:WarrantMember 2016-01-01 2016-03-31 0001593549 NUGN:ExercisePriceOneMember us-gaap:WarrantMember 2016-03-31 0001593549 NUGN:ExercisePriceTwoMember us-gaap:WarrantMember 2016-01-01 2016-03-31 0001593549 NUGN:ExercisePriceTwoMember us-gaap:WarrantMember 2016-03-31 0001593549 NUGN:ExercisePriceThreeMember us-gaap:WarrantMember 2016-01-01 2016-03-31 0001593549 NUGN:ExercisePriceThreeMember us-gaap:WarrantMember 2016-03-31 0001593549 us-gaap:WarrantMember 2016-03-31 0001593549 NUGN:ConsultingAgreementMember 2016-01-01 2016-03-31 0001593549 NUGN:AdvisoryAgreementsMember 2016-01-01 2016-03-31 0001593549 NUGN:AspMember 2016-03-31 0001593549 NUGN:CwmMember 2016-03-31 0001593549 NUGN:AliKharazmiMember 2016-03-31 0001593549 NUGN:SaeedKharazmiMember 2016-03-31 0001593549 NUGN:FifteenPercentNoteMember 2016-03-31 0001593549 NUGN:TenPercentNoteMember 2016-03-31 0001593549 NUGN:AdvancesMember 2016-03-31 0001593549 NUGN:FifteenPercentNoteMember 2016-01-01 2016-03-31 0001593549 NUGN:TenPercentNoteMember 2016-01-01 2016-03-31 0001593549 NUGN:AdvancesMember 2016-01-01 2016-03-31 0001593549 NUGN:FifteenPercentNoteMember 2015-09-25 0001593549 NUGN:TenPercentNoteMember 2015-11-30 0001593549 NUGN:TenPercentNoteMember 2015-11-01 2015-11-30 0001593549 2015-11-30 0001593549 NUGN:ExercisePriceFourMember us-gaap:WarrantMember 2016-01-01 2016-03-31 0001593549 NUGN:ExercisePriceFourMember us-gaap:WarrantMember 2016-03-31 0001593549 2015-03-31 0001593549 NUGN:FifteenPercentNoteMember 2015-09-01 2015-09-25 0001593549 NUGN:EmpolyeeMember NUGN:CommonStockOptionsMember 2015-08-14 0001593549 2016-05-20 0001593549 NUGN:OneCustomerMember us-gaap:SalesRevenueNetMember 2016-01-01 2016-03-31 0001593549 NUGN:OneCustomerMember us-gaap:AccountsReceivableMember 2016-03-31 0001593549 NUGN:OneCustomerMember us-gaap:AccountsReceivableMember 2016-01-01 2016-03-31 0001593549 2015-01-01 2015-12-31 0001593549 NUGN:AdvancesOneMember 2016-03-31 0001593549 NUGN:AdvancesOneMember 2016-01-01 2016-03-31 0001593549 NUGN:FifteenPercentNoteMember 2015-12-31 0001593549 NUGN:TenPercentNoteMember 2015-12-31 0001593549 NUGN:AdvancesMember 2015-12-31 0001593549 NUGN:AdvancesOneMember 2015-12-31 0001593549 2016-03-30 0001593549 NUGN:AdvisoryAgreementsMember 2015-01-01 2015-03-31 0001593549 NUGN:EmpolyeeMember NUGN:CommonStockOptionsMember 2016-01-01 2016-03-31 0001593549 us-gaap:SubsequentEventMember NUGN:CanyonAssetsHoldingsIncMember 2016-04-01 2016-04-04 0001593549 us-gaap:SubsequentEventMember NUGN:JtsNoteMember 2016-04-01 2016-04-04 0001593549 us-gaap:SubsequentEventMember NUGN:JtsNoteMember 2016-04-04 0001593549 us-gaap:SubsequentEventMember NUGN:GeminiMasterFundMember 2016-04-01 2016-04-04 0001593549 us-gaap:SubsequentEventMember NUGN:GeminiMasterFundMember 2016-04-04 0001593549 us-gaap:SubsequentEventMember NUGN:TwoEmployeesMember 2016-05-31 0001593549 us-gaap:SubsequentEventMember NUGN:TwoEmployeesMember us-gaap:MinimumMember 2016-05-31 0001593549 us-gaap:SubsequentEventMember NUGN:TwoEmployeesMember us-gaap:MaximumMember 2016-05-31 0001593549 us-gaap:SubsequentEventMember 2016-04-30 0001593549 us-gaap:SubsequentEventMember 2016-05-31 0001593549 us-gaap:SubsequentEventMember 2016-05-01 2016-05-06 0001593549 2014-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure NuGene International, Inc. 10-Q 2016-03-31 false 0001593549 --12-31 Smaller Reporting Company Yes No No 2016

50000

1917720

39894673

40024673

0.0001

25000000

1917720

0.0001

100000000

39894673

40024673

50000

-350000

-1077082

-240626

147110

303957

66188

177403

213298

481360

50000

1000000

263037

163108

244975

50000

575000

275000

.01

0.46

0.18

0.855

0.05

177140

29946

51291

72287

81083

105205

204399

50000 P2Y P8Y P8Y

13594

5172

430838

75000

0.15

0.10

30467

43521

2420

1000000 The holder may also convert any unpaid principal under the 10% Note into any funding instrument entered into by our Company for a period of 180 days after the date of the 10% Note. The full interest of 10% of the borrowings under the 10% Note ($5,000) is due irrespective of whether paid at maturity or when required to be prepaid.

410000

244975

15259 82351 51111

171825

-905257

-240626

500000

0.15

0.10

5333

36398

40374

294955

40024673

347048

383627

327893

-114052

-693120

-30631

-136748

215325

-96758

406013

45833

53672

171481

107990

-8504

36579

225090

2700

13594

80172

112818

336686

40374

4540

82699

22907

149290

618918

1344737

126383

-725819

244975

50000

302283

218116

39959673

39197400

-0.03

-0.01

2700

P4Y

50000

100000

50000

40620

54214

248970

253510

104166

136585

141125

8219

1204975

500000

50000

410000

244975

842504

1200297

500000

50000

405322

244975

500000

50000

292504

35052 92490 75000 3803 13687 31479 1383 2190 1286111 500000 50000 461111 275000 138333 11496

2016-04-04

2016-05-15

2016-12-31

37936

253261

178044

34000

14029

27188

877673

1327144

-383366

-1001095

-6568507

-7645589

6180929

6640257

3990

4003

192

1261039

2328239

17924

48555

35052

92490

327623

733636

877673

1327144

-21321

208350

199296

648002

1106527

26509

80181

177492

285482

74046

85280

842504

1200297

57617

74077

547378 94086

154389

162021

1052367

544583

57438

11234

122667

200000

128000

0.001

1.50

2.00

2.50

1350000

50000

300000

2200000

500000

P1Y8M19D

P2Y7M13D

P4Y7M17D

P5Y

450000

50000

300000

800000

50000

P18M

50000

200000

1000000

-95000

145670

198935

204585

210234

106530

865954

16637

49913

36000

70000

0.03

31000

49998

500000

275000

75000

575000

0.15

0.08

245000 0.18

The Gemini Note is convertible in part (subject to a $10,000 minimum) at the option of Gemini into shares of the Company’s common stock at the rate of $0.70 per share

1.12 1500000

0.25

0.70

1000000

0.55

1.50

NOTE 1 NATURE OF BUSINESS AND BASIS OF PRESENTATION    NuGene International, Inc. (the Company or NGI) was incorporated in the State of Nevada on October 31, 2013. NuGene, Inc. (our wholly owned subsidiary) was incorporated in the state of California in December 2006. On January 20, 2015, we formed NuGene BioPharma, Inc. (BioPharma) as a wholly owned California incorporated subsidiary of NGI. On November 6, 2015, we formed The Aesthetic Group, Inc. (TAG) as a wholly owned California incorporated subsidiary of NGI. Both BioPharma and TAG had no significant independent operations during 2015.    Basis of Presentation The accompanying unaudited condensed consolidated financial statements of our Company have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and applicable regulations of the U.S. Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been omitted pursuant to such rules and regulations. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of financial position and results of operations have been included. Our operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2015, which are included in our Annual Report on Form 10-K.   The accompanying condensed consolidated financial statements reflect the accounts of NuGene International, Inc. and its wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.   We have incurred net losses through the date of these financial statements and have yet to establish profitable operations. Our financial statements have been presented on the basis that our business is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We are subject to the risks and uncertainties associated with a business with high short-term debt, limited commercial product revenues, including limitations on our operating capital resources and uncertain demand for our products. We have incurred recurring operating losses and negative operating cash flows in 2015 and through March 31, 2016, and we expect to continue to incur operating losses and negative operating cash flows at least through the near future. Members of our Companys management have been required to advance our Company funding in order to partially meet our most critical cash requirements including payroll along with those associated with certain critical goods and services. In the process of managing these situations, our management may have made representations implying their personal guarantee of certain of our Companys obligations, irrespective of whether such guarantees are legally valid and enforceable.   As a result of the aforementioned factors, management has concluded that there is substantial doubt about our ability to continue as a going concern. Our independent registered public accounting firm, in its report on our 2015 consolidated financial statements, raised substantial doubt about our ability to continue as a going concern. Our consolidated financial statements as of and for the three months ended March 31, 2016 do not contain any adjustments for this uncertainty. In response to our Companys cash needs, we raised funding as described in our footnotes that follow. Any additional amounts raised will be used for our future investing and operating cash flow needs. However, there can be no assurance that we will be successful in raising additional amounts of financing.

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Significant Accounting Policies There have been no material changes in the Companys significant accounting policies to those previously disclosed in the 2015 Annual Report.   Use of Estimates Conformity with Generally Accepted Accounting Principles (GAAP) requires the use of estimates and judgments that affect the reported amounts in the financial statements and accompanying notes. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities that are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. GAAP requires us to make estimates and judgments in several areas, including but not limited to, those related to revenue recognition, collectability of accounts receivable, contingent liabilities, fair value of financial instruments, fair value of acquired intangible assets and goodwill, useful lives of intangible assets and property and equipment, excess and obsolete inventory, deferred tax asset valuation and income taxes. These estimates are based on managements knowledge about current events and expectations about actions we may undertake in the future. Actual results could differ materially from those estimates.   Reclassifications For comparability, certain prior period amounts have been reclassified, where appropriate, to conform to the current years financial statement presentation. These reclassifications have no impact on net loss.   Concentration of Revenues During the three months ended March 31, 2016, we derived 18% of our revenues from one customer. During the three months ended March 31, 2015, we derived 46% of our revenues from a single wholesale distributor. Our distributors purchase products from us on a purchase order basis on standard terms. The distributors are under no obligation to continue to purchase our products. The loss of any of our major distributors, a material reduction in their purchases or the cancellation of product orders or unexpected returns of unsold products could significantly decrease our revenues and impede our future growth prospects. We do not have long-term purchase commitments with our distributors.   Research and Development Internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed. Research and development consists of consulting fees, direct labor and raw materials associated with the development of new products to be commercialized by our Company. Research and development expenses totaled $29,946 and $51,291 for the three months ended March 31, 2016 and 2015, respectively.   Allowance for Doubtful Accounts Our Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Our allowance for doubtful accounts was $177,140 at March 31, 2016 and December 31, 2015. Bad debt expense totaled $2,700 for the three months ended March 31, 2015. At March 31, 2016, we have $327,893 outstanding in accounts receivable from one customer. This balance represents 85.5% of net accounts receivable at March 31, 2016, and none of this balance is included in our allowance for doubtful accounts as of that date. The products represented by this outstanding balance were shipped in December 2015 under extended payment terms of 90 days. As of March 31, 2016, the invoice was past due, however management believes that the full account is recoverable.   Prepaid Consulting Prepaid consulting represents amounts paid with restricted stock awards for future contractual benefits to be received. The fair value of these restricted stock awards is recorded to prepaid consulting and additional paid-in capital, upon issuance of the shares, and then amortized to the statements of operations over the life of the contracts using the straight-line method. On March 17, 2016, the Company entered into a 12 month consulting arrangement with an unrelated party. The Company granted 200,000 shares which were valued based upon the Companys closing price on the date of grant. The Company recorded prepaid consulting of $122,667 as of March 31, 2016 and the Company recognized SGA totaling $5,333 for the three months ended March 31, 2016 in connection with this agreement.   Recent Accounting Standards Updates In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842). ASU No. 2016-02 requires an entity to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. ASU No. 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. The Company currently in the process of evaluating the impact of adoption of ASU No. 2016-02 on the condensed consolidated financial statements and related disclosures.   In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations. The purpose of ASU No. 2016-08 is to clarify the implementation of guidance on principal versus agent considerations. The amendments in ASU No. 2016-08 are effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently assessing the impact of ASU No. 2016-08 on the condensed consolidated financial statements and related disclosures.   In March 2016, the FASB issued ASU No. 2016-09, Compensation Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendment is to simplify several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in ASU No. 2016-09 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company is currently assessing the impact of ASU No. 2016-09 on the condensed consolidated financial statements and related disclosures.   Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. Our Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

NOTE 3 INVENTORIES   Inventories consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">March 31, 2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 70%; text-align: left">Raw materials</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">81,083</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 13%; text-align: right">72,287</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: left">Finished goods</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">204,399</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">105,205</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: left">Total Inventories</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">285,482</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">177,492</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

NOTE 4 INTANGIBLE ASSETS   Licensee Agreement In November 2014, we entered into a License Agreement with kathy ireland Worldwide® ("kiWW®") under which we licensed the right to utilize the trademarks and rights to the name, likeness and visual representations of Kathy Ireland (KI) in connection with our cosmeceutical line of products. The initial term of the license is for eight years and it may be renewed at the option of our Company for up to an additional four years. In accordance with the License Agreement, we will pay 5% of the net sales for all licensed products sold and collected under the licensed marks or a minimum guaranteed royalty of $100,000 in year one, which includes the period from approximately November 4, 2014 through December 31, 2015 (Contract Year 1) of the License Agreement. The minimum guaranteed royalty increases $50,000 each year in years two through eight of the License Agreement. We recognized $50,000 and $100,000 in royalty fees during the three months ended March 31, 2016 and the year ended December 31, 2015, respectively.   Additionally, we are obligated to pay an annual Brand Participation Fee to kiWW® which provides for general advertising, good will and promotion of the KI brand. NuGene prepaid kiWW $350,000 effective upon execution of the License as a Brand Participation fee for Contract Year 1. The Brand Participation Fee for Contract Years 2 through 8 is $50,000 annually (Year 2 having been completely recognized in the three months ended March 31, 2016) with an additional 1% of the total gross sales of Licensed Products of the prior year beginning in Contract Year 4. Our Company is currently in arrears with respect to the payment of the Year 2 fee that was due in November 2015. Such payment arrears could be construed as an event of default under the License Agreement and could be a cause for its annulment.

NOTE 5 PROPERTY AND EQUIPMENT   Property and equipment, net consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">March 31, 2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%; text-align: left">Software / website development</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">8,219</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">8,219</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Equipment</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">141,125</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">136,585</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; text-align: left">Leasehold improvements</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">104,166</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">104,166</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Property and equipment, gross</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">253,510</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">248,970</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; text-align: left">Accumulated depreciation</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">(54,214</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(40,620</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: left">Property and equipment, net</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">199,296</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">208,350</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Depreciation expense for the three months ended March 31, 2016 and 2015 was $13,594 and $5,172, respectively.

NOTE 6 PROMISSORY NOTES PAYABLE AND ADVANCES   On September 25, 2015, we entered into a Securities Purchase Agreement and issued a 15% Promissory Note with the principal face value of $500,000 (the 15% Note) to an accredited investor. Under the terms of the 15% Note, all principal and related accrued interest outstanding are due and payable to the noteholder upon the earlier of: (i) September 25, 2016; or (ii) within ten business days after the consummation of an equity or convertible debt financing with aggregate gross proceeds of at least $1,000,000.   Borrowings made pursuant to the 15% Note bear interest at the annual rate of 15% (or $75,000), irrespective of whether paid at or prior to September 25, 2016.  If any amount payable pursuant to the note payable is not paid when due (without regard to any applicable grace periods as set forth in the Note), whether at stated maturity, by acceleration or otherwise, such overdue amount shall bear interest at the rate of 15% from the date of such non-payment until such amount is paid in full. We recognized $ 43,521 in interest expense during the three months ended March 31, 2016 based on an estimated repayment date of April 4, 2016 (see subsequent events footnote below).   During November 2015, we issued a one year 10% promissory notes payable (the 10% Note) to a purchaser for cash proceeds totaling $50,000. In the event that we secure any future financing with aggregate gross proceeds of at least $1 million while the 10% Note is outstanding, the 10% Note and all accrued interest therefrom will be immediately due and payable within ten business days of the closing of such financing. The holder may also convert any unpaid principal under the 10% Note into any funding instrument entered into by our Company for a period of 180 days after the date of the 10% Note. The full interest of 10% of the borrowings under the 10% Note ($5,000) is due irrespective of whether paid at maturity or when required to be prepaid. We have recognized $2,420 in interest expense during the three months ended March 31, 2016 based on an estimated repayment date of May 15, 2016.   On November 30, 2015 and on four subsequent dates during December 2015, four individuals (the Lenders) advanced a total of $410,000 to the Company. The borrowings (Advances) were not accompanied by documentation of the nature of the Advances. However, there were general discussions as to the repayment terms, the interest expected to be paid to the Lenders and additional equity of the Company to be issued to the Lenders in connection with the Advances. Accordingly, we have accounted for the Advances based on estimates of their still undocumented final terms.   On March 30, 2016, a corporation advanced our Company $244,975. The advance was undocumented but our Company subsequently entered into an agreement with the corporation on terms documented in the subsequent events footnote that follows. The amounts advanced were accounted for at the value of the cash received as of March 31, 2016.   In connection with the expected value of the warrants, we recorded an equity contribution of $138,333 in December 2015 ($82,351 and $15,259 of which was amortized and charged to interest expense during the three months ended March 31, 2016 and December 31, 2015, respectively). We calculated an original issue discount of $51,111 on the borrowings ($30,467 of which was charged to interest expense during the three months ended March 31, 2016) and we have recognized $11,496 of interest during the three months ended March 31, 2016 for the expected interest to be paid on the non-discounted face value of the borrowings.   Borrowings under notes payable and advances as of March 31, 2016 and December 31, 2015 are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Company  Proceeds</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Carrying  Value at  March 31,  2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Carrying  Value at  December  31, 2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Accrued  Interest at  March 31,  2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Accrued  Interest at  December  31, 2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; text-align: center">Principal  Value at  Maturity</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: justify"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 34%; text-align: justify">15% Note</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">500,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">500,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">500,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">75,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">31,479</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">500,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">10% Note</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,803</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,383</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Advances - 2015</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">410,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">405,322</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">292,504</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">13,687</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,190</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">461,111</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify">Advances - 2016</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">244,975</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">244,975</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">-</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">-</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">-</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">275,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">1,204,975</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">1,200,297</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">842,504</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">92,490</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">35,052</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,286,111</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

NOTE 7 STOCKHOLDERS EQUITY   Common Stock Our Company has Advisory Agreements with members of its Advisory Board. The terms of the individual Advisory Agreements vary and provide for up to 50,000 initial sign-on shares vesting for a maximum of an 18-month period, and up to 50,000 shares of common stock per annum issued on the anniversary of the effective date of the agreement. Expenses for the issuance of common stock for services related to these share issuances is recognized over the service period in which the shares are earned or over the respective vesting period, as applicable, and is calculated based on the average closing price per share of our common stock, during the respective quarter, as quoted on the OTC Marketplace. Selling, general and administrative expenses (SGA) recognized in connection with the Advisory Agreements totaled $36,398 and $40,374 for the three months ended March 31, 2016 and 2015, respectively.   On March 17, 2016, we entered into a consulting agreement for services over one year. In connection with the agreement, we granted the consultant 200,000 shares of our fully vested common stock as consideration for the consultants services. The Company recorded prepaid consulting of $122,667 as of March 31, 2016 and the Company recognized SGA totaling $5,333 for the three months ended March 31, 2016 in connection with this agreement.   Common Stock Options On August 14, 2015, we granted an option to purchase up to 1,000,000 shares of our common stock to each of two employees. We recognized $294,955 of SGA as stock based compensation in connection with the vesting of the options during three months ended March 31, 2016.   Common Stock Warrants Our Company has issued warrants to purchase shares of our common stock to accredited investors and consultants as compensation for services rendered, as well as, in conjunction with the purchase of our common stock. A summary of the Companys warrants activity and related information as of March 31, 2016 is as follows.   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center">Stock Warrants Outstanding as of March 31, 2016</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center">Exercise</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: center">Warrants</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: center">Remaining</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: center">Warrants</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Granted</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Life (Years)</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercisable</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; text-align: left">$</td> <td style="width: 23%; text-align: right">0.001</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 22%; text-align: right">1,350,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 22%; text-align: right">1.72</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 22%; text-align: right">450,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">$</td> <td style="text-align: right">1.50</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">2.62</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">$</td> <td style="text-align: right">2.00</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">300,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">4.63</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">300,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">2.50</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">500,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">5.00</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 2.25pt double; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">2,200,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">800,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

NOTE 8 RELATED PARTY TRANSACTIONS   The following individuals and entities have been identified as related parties based on their affiliation with our CEO and Chairman of the Board:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 52%; text-align: justify">Ali Kharazmi</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="width: 47%; text-align: justify">Chief Executive Officer, President, Board Member and greater than 10% shareholder</td></tr> <tr> <td style="text-align: justify">Saeed  Kharazmi</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: justify">Chairman of the Board, Acting Chief Financial Officer and greater than 10% shareholder</td></tr> <tr> <td style="text-align: justify">Genetics Institute of Anti-Aging</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: justify">Company with common ownership and management</td></tr> <tr> <td style="text-align: justify">Applied M.A.K. Enterprises, Inc. (MAK)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: justify">Company with common ownership and management</td></tr> <tr> <td style="text-align: justify">Advanced Surgical Partners, LLC (AdvSP)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: justify">Company with common ownership and management</td></tr> <tr> <td style="text-align: justify">Center for Weight Management & Plastic Surgery (CWM)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: justify">Company with common ownership and management</td></tr> <tr> <td style="text-align: justify">Center for Regenerative Science, LLC</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: justify">Company with common ownership and management</td></tr> </table>   The following amounts were owed to related parties, affiliated with the CEO and Chairman of the Board, at the dates indicated:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; text-align: center">March 31,   2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 81%; text-align: left">AdvSP</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">178,044</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">CWM</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">34,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Ali Kharazmi</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,029</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: left">Saeed Kharazmi</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">27,188</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 0.1in; text-align: left; text-indent: -0.1in">Accounts payable - related parties</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">253,261</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The amount owed to AdvSP relates to legal and administrative services provided by AdvSP employees to our Company. Our Company temporarily advanced $95,000 to AdvSP prior to December 31, 2015 and was repaid in full prior to January 5, 2016. The amount owed to CWM relates to medical procedures provided to NuGene consultants as compensation for advertising and marketing services provided to NuGene. The amount owed to Ali and Saeed Kharazmi and all amounts outstanding represent advances that bore no interest and were due on demand or expense reimbursements incurred in the ordinary course of business.

NOTE 10 SUBSEQUENT EVENTS   On April 4, 2016, we issued a note payable to Canyon Assets Holdings, Inc. (Lender) dated March 28, 2016 in the principal amount of $575,000. The note was issued to the Lender in consideration for the Lenders having satisfied on the Companys behalf an outstanding note payable (the CAH Note) of the Company (the JTS Note). The JTS Note issued September 25, 2015 was repaid in full ($500,000 face value and accrued interest of $75,000) by the Lender with the payment of $575,000 in cash. The terms of the CAH Note call for an interest rate of 15%, due one year from the date of the CAH Note. However, all accrued and unpaid interest and all other amounts payable under the CAH Note are due to the Lender within ten (10) business days after the closing by the Company of an equity or convertible debt financing in one or more series of transactions, with aggregate gross proceeds of at least $1 million.   On April 4, 2016, we issued a $275,000 face value note payable and 50,000 shares of our common stock to Gemini Master Fund, LTD (Gemini) pursuant to a Security Purchase Agreement dated March 30, 2016 (the date the funds were received by our Company). Under the terms of the related note payable (the Gemini Note), the Company received $245,000, net of costs and original issue discount. Other significant terms of the Gemini Note include:    <table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 72px; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"></td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: justify">A maturity date of December 31, 2016 in the absence of events triggering mandatory early repayment (as summarized below);</td></tr> </table> <table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 72px; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"></td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: justify">Interest accrues at the rate of 8% on the $275,000 face value (18% in the event of an event of default as defined in the Gemini Note);</td></tr> </table> <table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 72px; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"></td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: justify">The Gemini Note is convertible in part (subject to a $10,000 minimum) at the option of Gemini into shares of the Companys common stock at the rate of $0.70 per share (subject to adjustment summarized below);</td></tr> </table> <table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 72px; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"></td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: justify">The Company has the option to prepay the Gemini Note;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 72px; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"></td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: justify">All prepayments of the Gemini Note, whether effected at the option of the Company or subject to mandatory early repayment (as summarized herein), require the Company to repay Gemini 112% of the outstanding principal and all outstanding accrued interest through the date of prepayment;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 72px; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"></td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: justify">All principal and interest outstanding under the Gemini Note are required to be immediately repaid should the Company complete a financing or series of financings totaling $1.5 million or more; and</td></tr> </table> <table cellspacing="0" cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 72px; font: 8pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; font: italic 8pt Times New Roman, Times, Serif"></td> <td style="font: italic 8pt Times New Roman, Times, Serif; text-align: justify">The Conversion price of the Gemini Note is adjusted for the following: 1) loss of Company DTC eligibility conversion price adjusts to $0.25 per share; 2) stock dividends and splits as described in the Gemini Note; 3) a rights offering below the market price (as defined) as described in the Gemini Note; 4) fundamental transactions (as defined) as described in the Gemini Note; 5) subsequent equity sales below $0.70 per share as more particularly detailed and described in the Gemini Note.</td></tr> </table>   The foregoing summaries of the agreements and of the CAH Note and Gemini Note are qualified in by the forms of the agreements included as exhibits to this report. The cash received prior to March 31, 2016 on the Gemini Note were included in notes and advances payable in the accompanying balance sheet as of that date.   In May 2016, we entered into agreements with two employees that hold options to purchase up to 1,000,000 shares of our common stock each. The agreements modified the strike price of their outstanding options from the previous strike prices of $1.50 to $0.55 per share. All other terms of the previous option agreements remained unchanged.

Significant Accounting Policies There have been no material changes in the Companys significant accounting policies to those previously disclosed in the 2015 Annual Report.

Use of Estimates Conformity with Generally Accepted Accounting Principles (GAAP) requires the use of estimates and judgments that affect the reported amounts in the financial statements and accompanying notes. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities that are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. GAAP requires us to make estimates and judgments in several areas, including but not limited to, those related to revenue recognition, collectability of accounts receivable, contingent liabilities, fair value of financial instruments, fair value of acquired intangible assets and goodwill, useful lives of intangible assets and property and equipment, excess and obsolete inventory, deferred tax asset valuation and income taxes. These estimates are based on managements knowledge about current events and expectations about actions we may undertake in the future. Actual results could differ materially from those estimates.

Reclassifications For comparability, certain prior period amounts have been reclassified, where appropriate, to conform to the current years financial statement presentation. These reclassifications have no impact on net loss.

Concentration of Revenues During the three months ended March 31, 2016, we derived 18% of our revenues from one customer. During the three months ended March 31, 2015, we derived 46% of our revenues from a single wholesale distributor. Our distributors purchase products from us on a purchase order basis on standard terms. The distributors are under no obligation to continue to purchase our products. The loss of any of our major distributors, a material reduction in their purchases or the cancellation of product orders or unexpected returns of unsold products could significantly decrease our revenues and impede our future growth prospects. We do not have long-term purchase commitments with our distributors.

Research and Development Internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed. Research and development consists of consulting fees, direct labor and raw materials associated with the development of new products to be commercialized by our Company. Research and development expenses totaled $29,946 and $51,291 for the three months ended March 31, 2016 and 2015, respectively.

Allowance for Doubtful Accounts Our Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Our allowance for doubtful accounts was $177,140 at March 31, 2016 and December 31, 2015. Bad debt expense totaled $2,700 for the three months ended March 31, 2015. At March 31, 2016, we have $327,893 outstanding in accounts receivable from one customer. This balance represents 85.5% of net accounts receivable at March 31, 2016, and none of this balance is included in our allowance for doubtful accounts as of that date. The products represented by this outstanding balance were shipped in December 2015 under extended payment terms of 90 days. As of March 31, 2016, the invoice was past due, however management believes that the full account is recoverable.

Prepaid Consulting Prepaid consulting represents amounts paid with restricted stock awards for future contractual benefits to be received. The fair value of these restricted stock awards is recorded to prepaid consulting and additional paid-in capital, upon issuance of the shares, and then amortized to the statements of operations over the life of the contracts using the straight-line method. On March 17, 2016, the Company entered into a 12 month consulting arrangement with an unrelated party. The Company granted 200,000 shares which were valued based upon the Companys closing price on the date of grant. The Company recorded prepaid consulting of $122,667 as of March 31, 2016 and the Company recognized SGA totaling $5,333 for the three months ended March 31, 2016 in connection with this agreement.

Recent Accounting Standards Updates In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842). ASU No. 2016-02 requires an entity to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. ASU No. 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. The Company currently in the process of evaluating the impact of adoption of ASU No. 2016-02 on the condensed consolidated financial statements and related disclosures.   In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations. The purpose of ASU No. 2016-08 is to clarify the implementation of guidance on principal versus agent considerations. The amendments in ASU No. 2016-08 are effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently assessing the impact of ASU No. 2016-08 on the condensed consolidated financial statements and related disclosures.   In March 2016, the FASB issued ASU No. 2016-09, Compensation Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendment is to simplify several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in ASU No. 2016-09 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company is currently assessing the impact of ASU No. 2016-09 on the condensed consolidated financial statements and related disclosures.   Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. Our Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">March 31, 2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 70%; text-align: left">Raw materials</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">81,083</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 13%; text-align: right">72,287</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: left">Finished goods</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">204,399</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">105,205</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: left">Total Inventories</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">285,482</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">177,492</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">March 31, 2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%; text-align: left">Software / website development</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right">8,219</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">8,219</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Equipment</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">141,125</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">136,585</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; text-align: left">Leasehold improvements</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">104,166</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">104,166</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Property and equipment, gross</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">253,510</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">248,970</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; text-align: left">Accumulated depreciation</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">(54,214</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(40,620</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: left">Property and equipment, net</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">199,296</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">208,350</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center">Stock Warrants Outstanding as of March 31, 2016</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center">Exercise</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: center">Warrants</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: center">Remaining</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: center">Warrants</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Granted</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Life (Years)</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercisable</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; text-align: left">$</td> <td style="width: 23%; text-align: right">0.001</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 22%; text-align: right">1,350,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 22%; text-align: right">1.72</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 22%; text-align: right">450,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">$</td> <td style="text-align: right">1.50</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">2.62</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">$</td> <td style="text-align: right">2.00</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">300,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">4.63</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">300,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">2.50</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">500,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">5.00</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 2.25pt double; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">2,200,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">800,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; text-align: center">March 31,   2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 81%; text-align: left">AdvSP</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">178,044</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">CWM</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">34,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Ali Kharazmi</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,029</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: left">Saeed Kharazmi</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">27,188</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 0.1in; text-align: left; text-indent: -0.1in">Accounts payable - related parties</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">253,261</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 80%; text-align: left">2016 (remainder)</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 17%; text-align: right">145,670</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">2017</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">198,935</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">2018</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">204,585</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">2019</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">210,234</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; text-align: left">2020</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">106,530</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: left">Total</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">865,954</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

NOTE 9 COMMITMENTS AND CONTINGENCIES   Commitments We sub-lease our sole corporate facilities at 17912 Cowan, Suite A, Irvine, California, 92614 from AdvSP, an affiliate of our Company, for approximately $16,637 per month (including common area maintenance), consistent with the amount that is charged to AdvSP by the property owner. On February 5, 2015, AdvSP entered into a new five-year lease for the property with the owner beginning July 1, 2015 and subsequently amended to begin June 1, 2015. The lease was subsequently amended to increase the square footage under lease beginning in January 2016. The lease includes annual increases in the monthly lease payments of approximately 3% each year.   At March 31, 2016, aggregate future minimum payments under the lease, including common area maintenance costs, are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 80%; text-align: left">2016 (remainder)</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 17%; text-align: right">145,670</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">2017</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">198,935</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">2018</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">204,585</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">2019</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">210,234</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; text-align: left">2020</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">106,530</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: left">Total</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">865,954</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   During the three month ended March 31, 2016 and 2015, we incurred rent expense totaling $49,913 and $36,000, respectively.   Delinquent Payroll Tax Payments/Returns The Company is delinquent in filing certain payroll tax returns resulting in the non-payment of the related withholdings and employer taxes. The delinquency and non-payments are for the quarterly period ended March 31, 2016. The total amount of money owed (excluding potential late filing and late payment penalties) at March 31, 2016 is approximately $70,000 (which is included in accounts payable and accrued expenses in the accompanying consolidated balance sheet at March 31, 2016).   Legal Proceedings   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"></td> <td style="text-align: center; width: 24px"></td> <td style="text-align: justify">On July 10, 2015 Stemage Skin Care, LLC (the Plaintiff) filed a complaint in the U.S. District Court for the Central District of California entitled Stemage Skin Care LLC, a North Carolina limited liability company vs. NuGene International, Inc. et al. (Civil Action No.8:15-cv-01078-AG-JCG). The complaint also names as defendants NuGene, Inc., Ali Kharazmi, Saeed Kharazmi, Kathy Ireland Worldwide, Stephen Roseberry, Steve Rosenblum and Erik Sterling. The complaint contains allegations of damage asserted to be grounded on: (i) copyright infringement; (ii) interference with contract; (iii) intentional interference with prospective economic advantage; (iv) negligent interference with prospective economic advantage; and (v) conspiracy. The complaint allegedly arises out of an August 20, 2012 agreement among the Plaintiff and kathy ireland inc. ("KI") pursuant to which KI made Kathy Ireland available to perform Ambassador Services" as defined within that agreement. That agreement effectively terminated in October 2014 and is the subject of a separate arbitration with KI and Kathy Ireland before the American Arbitration Association. We filed a response denying all claims and based on our review of the matter, we believe that the complaint is without merit. Early stages of discovery have been completed and we have agreed to stay further discovery and motions during settlement discussions between Plaintiff and KI. Notwithstanding, no assurance of outcome currently can be given.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 24px; text-align: justify">  </td> <td style="text-align: justify">On July 31, 2015 Star Health & Beauty, LLC (SH&B) filed a complaint in the U.S. District Court for the Northern District of Georgia entitled Star Health & Beauty, LLC vs. NuGene, Inc. and NuGene International, Inc. Defendants (Case No. 1:15-cv-02634-CAP). The complaint alleges that our use of the NUGENE name and trademark infringes on SH&Bs NUGEN name. SH&B seeks cancelation of our NUGENE trademark, as well as unspecified monetary damages. We are in the process of early discovery to assist us in evaluating the merits of this lawsuit and intend to defend our intellectual property rights vigorously. As this matter is at an early stage, no assurance of outcome currently can be given.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 24px; text-align: justify">  </td> <td style="text-align: justify">In October 2015, NSE Products, Inc., (NSE) a Delaware corporation based in Provo, Utah, initiated actions in the US Patent and Trademark Office contesting several of the Company's trademark registrations and applications. These actions, including Oppositions to trademark applications and Petitions to Revoke registered marks, rely on assertions made by NSE regarding the purported likelihood of confusion and dilution of NSE's trademarks that include the words NU SKIN. The Parties are discussing favorable settlement terms and we expect the matter will be resolved soon.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 24px; text-align: justify">  </td> <td style="text-align: justify">In May 2016, we were informed that the California Labor Commissioner scheduled a hearing in connection with two individuals that claimed our Company did not fulfill its obligations to pay a final paycheck. The two individuals are seeking back pay and penalties totaling approximately $31,000. Although we intend to contest various aspects of each claim, we recognize our Company may be held liable and accrued our best estimate of the eventual amount of the settlement.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 24px; text-align: justify">  </td> <td style="text-align: justify">On May 6, 2016, we were presented with a demand for payment of compensation for a former executive employee (the Executive) pursuant to his employment contract with our Company. The amount of the compensation claimed by the Executive totaled $49,998. Our Companys management is evaluating the merits of this matter. No amounts have been accrued in connection with this matter through March 31, 2016 as it reflected the Executives termination of employment on April 6, 2016.</td></tr> </table>   From time to time, we may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate) may materially and adversely affect our financial condition, results of operations and liquidity. In addition, the ultimate outcome of any litigation is uncertain. Any outcome (including any for the actions described above), whether favorable or unfavorable, may materially and adversely affect us due to legal costs and expenses, diversion of management attention and other factors. We expense legal costs in the period incurred. We cannot assure you that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against us in the future, and these matters could relate to prior, current or future transactions or events.   Other than that described above, we are not currently a party to any other material legal proceedings. We are not aware of any pending or threatened litigation against us that in our view would have a material adverse effect on our business, financial condition, liquidity, or operating results. However, legal claims are inherently uncertain, and we cannot assure you that we will not be adversely affected in the future by legal proceedings.

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Company  Proceeds</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Carrying  Value at  March 31,  2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Carrying  Value at  December  31, 2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Accrued  Interest at  March 31,  2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Accrued  Interest at  December  31, 2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td> <td nowrap="nowrap" colspan="2" style="border-bottom: black 1pt solid; text-align: center">Principal  Value at  Maturity</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td colspan="2" style="text-align: justify"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 34%; text-align: justify">15% Note</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">500,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">500,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">500,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">75,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">31,479</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">500,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">10% Note</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,803</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,383</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Advances - 2015</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">410,000</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">405,322</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">292,504</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">13,687</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,190</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td> <td style="text-align: right">461,111</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify">Advances - 2016</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">244,975</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">244,975</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">-</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">-</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">-</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">275,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">1,204,975</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">1,200,297</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">842,504</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">92,490</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">35,052</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: black 2.25pt double; text-align: left">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,286,111</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

EX-101.SCH 6 nugn-20160331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PROMISSORY NOTES PAYABLE AND ADVANCES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - PROMISSORY NOTES PAYABLE AND ADVANCES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - PROMISSORY NOTES PAYABLE AND ADVANCES (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - PROMISSORY NOTES PAYABLE AND ADVANCES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 nugn-20160331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 nugn-20160331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 nugn-20160331_lab.xml XBRL LABEL FILE kiWW [Member] Related Party [Axis] Unaffiliated accredited investor [Member] Series A Preferred Stock [Member] Class of Stock [Axis] Restricted Stock [Member] Award Type [Axis] Mr. O'Brien [Member] AdvSP [Member] MAK [Member] Ali Kharazmi [Member] Saeed Kharazmi [Member] Single Wholesale Distributor [Member] Two Wholesale Distributor [Member] Minimum [Member] Range [Axis] Maximum [Member] Leasehold Improvements [Member] Property, Plant and Equipment, Type [Axis] Equipment [Member] Software / website development [Member] Website Development [Member] Consultants [Member] Ms. Kurland [Member] Business Acquisition [Axis] Common Stock [Member] Advisory Agreements [Member] Board of Directors [Member] Title of Individual [Axis] Revenue [Member] Concentration Risk Benchmark [Axis] SGIP [Member] Exercise Price $0.001 [Member] Exercise Price Range [Axis] Warrant [Member] Exercise Price $1.50 [Member] Exercise Price $2.00 [Member] Common Stock Options [Member] Employees [Member] Common Stock Warrants [Member] Former Consultant [Member] OTC Marketplace [Member] Consulting agreement [Member] Chief Executive Officer [Member] Chairman of the Board [Member] Series A Convertible Preferred Stock [Member] CWM [Member] Preferred Stock Equity Components [Axis] Common Stock Additional Paid-In Capital Treasury Stock Accumulated Deficit 15% Note [Member] Subordinated Borrowing [Axis] 10% Note [Member] Advances 2015 [Member] Exercise Price 2.50 [Member] Empolyee [Member] KBHJJ, LLC [Member] Less amounts advanced to AdvSP and repaid in January 2016 [Member] Common Stock Earned but Unissued Wholesale Distributor [Member] Officers [Member] One Customer [Member] Accounts Receivable [Member] Advances 2016 [Member] Subsequent Event [Member] Subsequent Event Type [Axis] Canyon Assets Holdings, Inc. [Member] Debt Instrument [Axis] JTS Note [Member] Gemini Master Fund, LTD [Member] Two employees [Member] Document and Entity Information: Entity Registrant Name Document Type Document Period End Date Amendment Flag Entity Central Index Key Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Entity Public Float Entity Filer Category Entity Current Reporting Status Entity Voluntary Filers Entity Well-known Seasoned Issuer Document Fiscal Year Focus Document Fiscal Period Focus Fresh-Start Balance Sheet [Abstract] ASSETS Current assets: Cash Accounts receivable, net of allowance for doubtful accounts of $177,140 on March 31, 2016 and December 31, 2015 Inventories Prepaid inventories Prepaid consulting Other current assets Total current assets Property and equipment, net of accumulated depreciation of $54,214 and $40,620 at March 31, 2016 and December 31, 2015, respectively Deposits Total assets Liabilities and Stockholders' Deficiency Current liabilities: Accounts payable and accrued expenses Accounts payable and advances - related parties Notes payable and advances Accrued interest Other current liabilities Total current liabilities Commitments and contingencies Stockholders' deficiency: Series A convertible preferred stock; $0.0001 par value; 25,000,000 shares authorized; 1,917,720 shares issued and outstanding on March 31, 2016 and December 31, 2015 Common stock; $0.0001 par value; 100,000,000 shares authorized; 40,024,673 and 39,894,673 shares issued and outstanding on March 31, 2016 and December 31, 2015, respectively Common stock earned but unissued; 218,116 and 302,283 shares as of March 31, 2016 and December 31, 2015, respectively Additional paid-in capital Accumulated deficit Total stockholders' deficiency Total liabilities and stockholders' equity (deficiency) Allowance for Doubtful Accounts Receivable Accumulated depreciation Series A convertible preferred stock, par value Series A convertible preferred stock, Authorized Series A convertible preferred stock, issued shares Series A convertible preferred stock, outstanding shares Common stock, par value Common stock, Authorized Common stock, Issued Common stock, outstanding Common stock earned but unissued Income Statement [Abstract] Revenues Cost of goods sold Gross profit Operating expenses: Advertising and promotion Personnel Selling, general and administrative Research and development Professional fees Total operating expenses Loss from operations Interest expense, net Net loss Weighted average number of common shares outstanding - basic and diluted Net loss per share - basic and diluted Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to cash flows from operating activities: Stock based compensation and stock issued for services Non-cash portion of interest expense Depreciation and amortization Bad debt expense Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid inventories Other assets Accounts payable and accrued expenses Accounts payable and advances - related parties Deferred revenues Accrued interest Other liabilities Cash flows from operating activities Cash flows from investing activities: Purchases of property and equipment Cash flows from financing activities: Proceeds from issuance of notes payable Proceeds from issuance of common stock Cash flows from financing activities Change in cash Cash, beginning of period Cash, end of period Supplemental disclosure of cash flow information: Cash paid for: Interest Income taxes Supplemental disclosure for non-cash activities: Prepaid consulting Disclosure Text Block [Abstract] NATURE OF BUSINESS AND BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Inventory Disclosure [Abstract] INVENTORIES Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Debt Disclosure [Abstract] PROMISSORY NOTES PAYABLE AND ADVANCES Equity [Abstract] STOCKHOLDERS' EQUITY EX-101.PRE 10 nugn-20160331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	May. 20, 2016
Document and Entity Information:
Entity Registrant Name	NuGene International, Inc.
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Entity Central Index Key	0001593549
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		40,024,673
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash	$ 149,290	$ 22,907
Accounts receivable, net of allowance for doubtful accounts of $177,140 on March 31, 2016 and December 31, 2015	383,627	347,048
Inventories	285,482	177,492
Prepaid inventories	85,280	$ 74,046
Prepaid consulting	122,667
Other current assets	80,181	$ 26,509
Total current assets	1,106,527	648,002
Property and equipment, net of accumulated depreciation of $54,214 and $40,620 at March 31, 2016 and December 31, 2015, respectively	199,296	208,350
Deposits	21,321	21,321
Total assets	1,327,144	877,673
Current liabilities:
Accounts payable and accrued expenses	733,636	327,623
Accounts payable and advances - related parties	253,261	37,936
Notes payable and advances	1,200,297	842,504
Accrued interest	92,490	35,052
Other current liabilities	48,555	17,924
Total current liabilities	$ 2,328,239	$ 1,261,039
Commitments and contingencies
Stockholders' deficiency:
Series A convertible preferred stock; $0.0001 par value; 25,000,000 shares authorized; 1,917,720 shares issued and outstanding on March 31, 2016 and December 31, 2015	$ 192	$ 192
Common stock; $0.0001 par value; 100,000,000 shares authorized; 40,024,673 and 39,894,673 shares issued and outstanding on March 31, 2016 and December 31, 2015, respectively	4,003	3,990
Common stock earned but unissued; 218,116 and 302,283 shares as of March 31, 2016 and December 31, 2015, respectively	42	30
Additional paid-in capital	6,640,257	6,180,929
Accumulated deficit	(7,645,589)	(6,568,507)
Total stockholders' deficiency	(1,001,095)	(383,366)
Total liabilities and stockholders' equity (deficiency)	$ 1,327,144	$ 877,673

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Fresh-Start Balance Sheet [Abstract]
Allowance for Doubtful Accounts Receivable	$ 177,140	$ 177,140
Accumulated depreciation	$ 54,214	$ 40,620
Series A convertible preferred stock, par value	$ 0.0001	$ 0.0001
Series A convertible preferred stock, Authorized	25,000,000	25,000,000
Series A convertible preferred stock, issued shares	1,917,720	1,917,720
Series A convertible preferred stock, outstanding shares	1,917,720	1,917,720
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, Authorized	100,000,000	100,000,000
Common stock, Issued	40,024,673	39,894,673
Common stock, outstanding	40,024,673	39,894,673
Common stock earned but unissued	218,116	302,283

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenues	$ 213,298	$ 481,360
Cost of goods sold	66,188	177,403
Gross profit	147,110	303,957
Operating expenses:
Advertising and promotion	57,617	74,077
Personnel	547,378	94,086
Selling, general and administrative	263,037	163,108
Research and development	29,946	51,291
Professional fees	154,389	162,021
Total operating expenses	1,052,367	544,583
Loss from operations	(905,257)	$ (240,626)
Interest expense, net	(171,825)
Net loss	$ (1,077,082)	$ (240,626)
Weighted average number of common shares outstanding - basic and diluted	39,959,673	39,197,400
Net loss per share - basic and diluted	$ (0.03)	$ (0.01)

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net loss	$ (1,077,082)	$ (240,626)
Adjustments to reconcile net loss to cash flows from operating activities:
Stock based compensation and stock issued for services	336,686	$ 40,374
Non-cash portion of interest expense	112,818
Depreciation and amortization	$ 13,594	$ 80,172
Bad debt expense		2,700
Changes in operating assets and liabilities:
Accounts receivable	$ (36,579)	(225,090)
Inventories	(107,990)	$ 8,504
Prepaid inventories	(11,234)
Other assets	(53,672)	$ (171,481)
Accounts payable and accrued expenses	406,013	45,833
Accounts payable and advances - related parties	$ 215,325	(96,758)
Deferred revenues		$ (136,748)
Accrued interest	$ 57,438
Other liabilities	30,631
Cash flows from operating activities	(114,052)	$ (693,120)
Cash flows from investing activities:
Purchases of property and equipment	(4,540)	$ (82,699)
Cash flows from financing activities:
Proceeds from issuance of notes payable	$ 244,975
Proceeds from issuance of common stock		$ 50,000
Cash flows from financing activities	$ 244,975	50,000
Change in cash	126,383	(725,819)
Cash, beginning of period	22,907	1,344,737
Cash, end of period	$ 149,290	$ 618,918
Cash paid for:
Interest
Income taxes
Supplemental disclosure for non-cash activities:
Prepaid consulting	$ 128,000

XML 16 R6.htm IDEA: XBRL DOCUMENT

NATURE OF BUSINESS AND BASIS OF PRESENTATION

3 Months Ended

Mar. 31, 2016

Disclosure Text Block [Abstract]

NATURE OF BUSINESS AND BASIS OF PRESENTATION

NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION

Basis of Presentation

XML 17 R7.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2016

Disclosure Text Block [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2015 Annual Report.

Use of Estimates

Reclassifications

Concentration of Revenues

Research and Development

Allowance for Doubtful Accounts

Prepaid Consulting

Recent Accounting Standards Updates

XML 18 R8.htm IDEA: XBRL DOCUMENT

INVENTORIES

3 Months Ended

Mar. 31, 2016

Inventory Disclosure [Abstract]

INVENTORIES

NOTE 3 – INVENTORIES

Inventories consist of the following:

	March 31, 2016		December 31, 2015
Raw materials	$	81,083	$	72,287
Finished goods		204,399		105,205
Total Inventories	$	285,482	$	177,492

XML 19 R9.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

NOTE 4 – INTANGIBLE ASSETS

Licensee Agreement

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT

3 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 5 – PROPERTY AND EQUIPMENT

Property and equipment, net consist of the following:

	March 31, 2016			December 31, 2015
Software / website development	$	8,219		$	8,219
Equipment		141,125			136,585
Leasehold improvements		104,166			104,166
Property and equipment, gross		253,510			248,970
Accumulated depreciation		(54,214	)		(40,620	)
Property and equipment, net	$	199,296		$	208,350

Depreciation expense for the three months ended March 31, 2016 and 2015 was $13,594 and $5,172, respectively.

XML 21 R11.htm IDEA: XBRL DOCUMENT

PROMISSORY NOTES PAYABLE AND ADVANCES

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

PROMISSORY NOTES PAYABLE AND ADVANCES

NOTE 6 – PROMISSORY NOTES PAYABLE AND ADVANCES

Borrowings under notes payable and advances as of March 31, 2016 and December 31, 2015 are summarized as follows:

	Company Proceeds		Carrying Value at March 31, 2016		Carrying Value at December 31, 2015		Accrued Interest at March 31, 2016		Accrued Interest at December 31, 2015		Principal Value at Maturity

15% Note	$	500,000	$	500,000	$	500,000	$	75,000	$	31,479	$	500,000
10% Note		50,000		50,000		50,000		3,803		1,383		50,000
Advances - 2015		410,000		405,322		292,504		13,687		2,190		461,111
Advances - 2016		244,975		244,975		-		-		-		275,000
	$	1,204,975	$	1,200,297	$	842,504	$	92,490	$	35,052	$	1,286,111

XML 22 R12.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

3 Months Ended

Mar. 31, 2016

Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 7 – STOCKHOLDERS’ EQUITY

Common Stock

Common Stock Options

Common Stock Warrants

Stock Warrants Outstanding as of March 31, 2016
Exercise		Warrants		Remaining		Warrants
Price		Granted		Life (Years)		Exercisable
$	0.001		1,350,000		1.72		450,000
$	1.50		50,000		2.62		50,000
$	2.00		300,000		4.63		300,000
$	2.50		500,000		5.00		-
			2,200,000				800,000

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

RELATED PARTY TRANSACTIONS

NOTE 8 – RELATED PARTY TRANSACTIONS

The following individuals and entities have been identified as related parties based on their affiliation with our CEO and Chairman of the Board:

Ali Kharazmi		Chief Executive Officer, President, Board Member and greater than 10% shareholder
Saeed Kharazmi		Chairman of the Board, Acting Chief Financial Officer and greater than 10% shareholder
Genetics Institute of Anti-Aging		Company with common ownership and management
Applied M.A.K. Enterprises, Inc. (“MAK”)		Company with common ownership and management
Advanced Surgical Partners, LLC (“AdvSP”)		Company with common ownership and management
Center for Weight Management & Plastic Surgery (“CWM”)		Company with common ownership and management
Center for Regenerative Science, LLC		Company with common ownership and management

The following amounts were owed to related parties, affiliated with the CEO and Chairman of the Board, at the dates indicated:

	March 31, 2016
AdvSP	$	178,044
CWM		34,000
Ali Kharazmi		14,029
Saeed Kharazmi		27,188
Accounts payable - related parties	$	253,261

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 9 – COMMITMENTS AND CONTINGENCIES

Commitments

At March 31, 2016, aggregate future minimum payments under the lease, including common area maintenance costs, are as follows:

2016 (remainder)	$	145,670
2017		198,935
2018		204,585
2019		210,234
2020		106,530
Total	$	865,954

During the three month ended March 31, 2016 and 2015, we incurred rent expense totaling $49,913 and $36,000, respectively.

Delinquent Payroll Tax Payments/Returns

Legal Proceedings

•

XML 25 R15.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2016

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 10 – SUBSEQUENT EVENTS

•

A maturity date of December 31, 2016 in the absence of events triggering mandatory early repayment (as summarized below);

•

Interest accrues at the rate of 8% on the $275,000 face value (18% in the event of an event of default as defined in the Gemini Note);

•

The Company has the option to prepay the Gemini Note;

•

All principal and interest outstanding under the Gemini Note are required to be immediately repaid should the Company complete a financing or series of financings totaling $1.5 million or more; and

•

XML 26 R16.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Mar. 31, 2016
Policy Text Block [Abstract]
Significant Accounting Policies	Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2015 Annual Report.
Use of Estimates	Use of Estimates Conformity with Generally Accepted Accounting Principles (“GAAP”) requires the use of estimates and judgments that affect the reported amounts in the financial statements and accompanying notes. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities that are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. GAAP requires us to make estimates and judgments in several areas, including but not limited to, those related to revenue recognition, collectability of accounts receivable, contingent liabilities, fair value of financial instruments, fair value of acquired intangible assets and goodwill, useful lives of intangible assets and property and equipment, excess and obsolete inventory, deferred tax asset valuation and income taxes. These estimates are based on management’s knowledge about current events and expectations about actions we may undertake in the future. Actual results could differ materially from those estimates.
Reclassifications	Reclassifications For comparability, certain prior period amounts have been reclassified, where appropriate, to conform to the current year’s financial statement presentation. These reclassifications have no impact on net loss.
Concentration of Revenues	Concentration of Revenues During the three months ended March 31, 2016, we derived 18% of our revenues from one customer. During the three months ended March 31, 2015, we derived 46% of our revenues from a single wholesale distributor. Our distributors purchase products from us on a purchase order basis on standard terms. The distributors are under no obligation to continue to purchase our products. The loss of any of our major distributors, a material reduction in their purchases or the cancellation of product orders or unexpected returns of unsold products could significantly decrease our revenues and impede our future growth prospects. We do not have long-term purchase commitments with our distributors.
Research and Development	Research and Development Internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed. Research and development consists of consulting fees, direct labor and raw materials associated with the development of new products to be commercialized by our Company. Research and development expenses totaled $29,946 and $51,291 for the three months ended March 31, 2016 and 2015, respectively.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts Our Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Our allowance for doubtful accounts was $177,140 at March 31, 2016 and December 31, 2015. Bad debt expense totaled $2,700 for the three months ended March 31, 2015. At March 31, 2016, we have $327,893 outstanding in accounts receivable from one customer. This balance represents 85.5% of net accounts receivable at March 31, 2016, and none of this balance is included in our allowance for doubtful accounts as of that date. The products represented by this outstanding balance were shipped in December 2015 under extended payment terms of 90 days. As of March 31, 2016, the invoice was past due, however management believes that the full account is recoverable.
Prepaid Consulting	Prepaid Consulting Prepaid consulting represents amounts paid with restricted stock awards for future contractual benefits to be received. The fair value of these restricted stock awards is recorded to prepaid consulting and additional paid-in capital, upon issuance of the shares, and then amortized to the statements of operations over the life of the contracts using the straight-line method. On March 17, 2016, the Company entered into a 12 month consulting arrangement with an unrelated party. The Company granted 200,000 shares which were valued based upon the Company’s closing price on the date of grant. The Company recorded prepaid consulting of $122,667 as of March 31, 2016 and the Company recognized SGA totaling $5,333 for the three months ended March 31, 2016 in connection with this agreement.
Recent Accounting Standards Updates	Recent Accounting Standards Updates In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842). ASU No. 2016-02 requires an entity to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. ASU No. 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. The Company currently in the process of evaluating the impact of adoption of ASU No. 2016-02 on the condensed consolidated financial statements and related disclosures. In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations”. The purpose of ASU No. 2016-08 is to clarify the implementation of guidance on principal versus agent considerations. The amendments in ASU No. 2016-08 are effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently assessing the impact of ASU No. 2016-08 on the condensed consolidated financial statements and related disclosures. In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. The amendment is to simplify several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in ASU No. 2016-09 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company is currently assessing the impact of ASU No. 2016-09 on the condensed consolidated financial statements and related disclosures. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. Our Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

XML 27 R17.htm IDEA: XBRL DOCUMENT

INVENTORIES (Tables)

3 Months Ended

Mar. 31, 2016

Inventory Disclosure [Abstract]

Inventories

	March 31, 2016		December 31, 2015
Raw materials	$	81,083	$	72,287
Finished goods		204,399		105,205
Total Inventories	$	285,482	$	177,492

XML 28 R18.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Tables)

3 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

Property and equipment

	March 31, 2016			December 31, 2015
Software / website development	$	8,219		$	8,219
Equipment		141,125			136,585
Leasehold improvements		104,166			104,166
Property and equipment, gross		253,510			248,970
Accumulated depreciation		(54,214	)		(40,620	)
Property and equipment, net	$	199,296		$	208,350

XML 29 R19.htm IDEA: XBRL DOCUMENT

PROMISSORY NOTES PAYABLE AND ADVANCES (Tables)

3 Months Ended

Mar. 31, 2016

Promissory Notes Payable And Advances Tables

Schedule Of borrowings notes payable and advances

	Company Proceeds		Carrying Value at March 31, 2016		Carrying Value at December 31, 2015		Accrued Interest at March 31, 2016		Accrued Interest at December 31, 2015		Principal Value at Maturity

15% Note	$	500,000	$	500,000	$	500,000	$	75,000	$	31,479	$	500,000
10% Note		50,000		50,000		50,000		3,803		1,383		50,000
Advances - 2015		410,000		405,322		292,504		13,687		2,190		461,111
Advances - 2016		244,975		244,975		-		-		-		275,000
	$	1,204,975	$	1,200,297	$	842,504	$	92,490	$	35,052	$	1,286,111

XML 30 R20.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Tables)

3 Months Ended

Mar. 31, 2016

Equity [Abstract]

Common stock warrants exercised

Stock Warrants Outstanding as of March 31, 2016
Exercise		Warrants		Remaining		Warrants
Price		Granted		Life (Years)		Exercisable
$	0.001		1,350,000		1.72		450,000
$	1.50		50,000		2.62		50,000
$	2.00		300,000		4.63		300,000
$	2.50		500,000		5.00		-
			2,200,000				800,000

XML 31 R21.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Tables)

3 Months Ended

Mar. 31, 2016

Material related party transactions

	March 31, 2016
AdvSP	$	178,044
CWM		34,000
Ali Kharazmi		14,029
Saeed Kharazmi		27,188
Accounts payable - related parties	$	253,261

XML 32 R22.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Tables)

3 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Aggregate future minimum payments under the lease

2016 (remainder)	$	145,670
2017		198,935
2018		204,585
2019		210,234
2020		106,530
Total	$	865,954

XML 33 R23.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Concentration Risk, Percentage	1.00%		5.00%
Research and development expenses	$ 29,946	$ 51,291
Allowance for doubtful accounts	177,140		$ 177,140
Accounts receivable	383,627		$ 347,048
Bad debt expense		$ 2,700
Prepaid consulting expense	122,667
SGA expense	$ 5,333
Shares granted or vested	200,000
One Customer [Member] \| Accounts Receivable [Member]
Concentration Risk, Percentage	85.50%
Accounts receivable	$ 327,893
One Customer [Member] \| Revenue [Member]
Concentration Risk, Percentage	18.00%
Single Wholesale Distributor [Member] \| Revenue [Member]
Concentration Risk, Percentage		46.00%

XML 34 R24.htm IDEA: XBRL DOCUMENT

INVENTORIES (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Inventories
Raw materials	$ 81,083	$ 72,287
Finished goods	204,399	105,205
Total Inventories	$ 285,482	$ 177,492

XML 35 R25.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
INTANGIBLE ASSETS (Details Narrative) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
License agreement term addition year renewed		4 years
License agreement term		8 years
Minimum guaranteed royalty		$ 100,000
Royalty fees expense	$ 50,000	100,000
Annual increments royalty expense		$ 50,000
Brand Participation Fee for Contract Years 2 through 8	$ 50,000
Revenue Percentage	1.00%	5.00%
Minimum [Member]
License agreement term	2 years
Maximum [Member]
License agreement term	8 years
kiWW [Member]
Brand Participation fee	$ 350,000

XML 36 R26.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Property and equipment, gross	$ 253,510	$ 248,970
Accumulated depreciation	(54,214)	(40,620)
Property and equipment, net	199,296	208,350
Software / website development [Member]
Property and equipment, gross	8,219	8,219
Equipment [Member]
Property and equipment, gross	141,125	136,585
Leasehold Improvements [Member]
Property and equipment, gross	$ 104,166	$ 104,166

XML 37 R27.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 13,594	$ 5,172

XML 38 R28.htm IDEA: XBRL DOCUMENT

PROMISSORY NOTES PAYABLE AND ADVANCES (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Company Proceeds	$ 1,204,975
Carrying Value	1,200,297	$ 842,504
Accrued Interest	92,490	35,052
Principal Value at Maturity	1,286,111
15% Note [Member]
Company Proceeds	500,000
Carrying Value	500,000	500,000
Accrued Interest	75,000	31,479
Principal Value at Maturity	500,000
10% Note [Member]
Company Proceeds	50,000
Carrying Value	50,000	50,000
Accrued Interest	3,803	1,383
Principal Value at Maturity	50,000
Advances 2015 [Member]
Company Proceeds	410,000
Carrying Value	405,322	292,504
Accrued Interest	13,687	$ 2,190
Principal Value at Maturity	461,111
Advances 2016 [Member]
Company Proceeds	244,975
Carrying Value	$ 244,975
Accrued Interest
Principal Value at Maturity	$ 275,000

XML 39 R29.htm IDEA: XBRL DOCUMENT

PROMISSORY NOTES PAYABLE AND ADVANCES (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
	Nov. 30, 2015	Sep. 25, 2015	Mar. 31, 2016	Mar. 31, 2015	Mar. 30, 2016	Dec. 31, 2015
Borrowings			$ 430,838
Interest expense			30,467
Cash proceeds from promissory notes payable			244,975
Advances	$ 410,000				$ 244,975
Equity contribution						$ 138,333
Amortized and charged interest expense			82,351			$ 15,259
Original issue discount borrowings			51,111
Recognized accrued interest			11,496
10% Note [Member]
Gross proceeds convertible promissory notes	$ 50,000
Convertible promissory notes rate	10.00%
Note bear interest	10.00%
Interest expense			$ 2,420
Maturity Date			May 15, 2016
Cash proceeds from promissory notes payable	$ 50,000
Aggregate gross proceeds from future financing	$ 1,000,000
Promissory notes payable description	The holder may also convert any unpaid principal under the 10% Note into any funding instrument entered into by our Company for a period of 180 days after the date of the 10% Note. The full interest of 10% of the borrowings under the 10% Note ($5,000) is due irrespective of whether paid at maturity or when required to be prepaid.
15% Note [Member]
Convertible promissory notes		$ 500,000
Gross proceeds convertible promissory notes		$ 1,000,000
Convertible promissory notes rate		15.00%
Borrowings		$ 75,000
Note bear interest		15.00%
Interest expense			$ 43,521
Maturity Date			Apr. 04, 2016

XML 40 R30.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details) - Warrant [Member]	3 Months Ended
STOCKHOLDERS' EQUITY (Details) - Warrant [Member]	Mar. 31, 2016 $ / shares shares
Warrants Granted	2,200,000
Warrants Exercisable	800,000
Exercise Price $0.001 [Member]
Exercise Price \| $ / shares	$ 0.001
Warrants Granted	1,350,000
Remaining Life (Years)	1 year 8 months 19 days
Warrants Exercisable	450,000
Exercise Price $1.50 [Member]
Exercise Price \| $ / shares	$ 1.50
Warrants Granted	50,000
Remaining Life (Years)	2 years 7 months 13 days
Warrants Exercisable	50,000
Exercise Price $2.00 [Member]
Exercise Price \| $ / shares	$ 2.00
Warrants Granted	300,000
Remaining Life (Years)	4 years 7 months 17 days
Warrants Exercisable	300,000
Exercise Price 2.50 [Member]
Exercise Price \| $ / shares	$ 2.50
Warrants Granted	500,000
Remaining Life (Years)	5 years
Warrants Exercisable

XML 41 R31.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	3 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Aug. 14, 2015
Selling, general and administrative expenses	$ 5,333
Shares issued to consultant	200,000
Prepaid consulting	$ 122,667
Advisory Agreements [Member]
Selling, general and administrative expenses	$ 36,398	$ 40,374
Shares issued advisor member each	50,000
Vesting period of shares	18 months
Restricted shares of common stock	50,000
Consulting agreement [Member]
Selling, general and administrative expenses	$ 5,333
Common Stock Options [Member] \| Empolyee [Member]
Selling, general and administrative expenses	$ 294,955
Warrant to purchase share of common stock				1,000,000

XML 42 R32.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Accounts payable - Related Parties	$ 253,261	$ 37,936
AdvSP [Member]
Accounts payable - Related Parties	178,044
CWM [Member]
Accounts payable - Related Parties	34,000
Ali Kharazmi [Member]
Accounts payable - Related Parties	14,029
Saeed Kharazmi [Member]
Accounts payable - Related Parties	$ 27,188

XML 43 R33.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative)	Dec. 31, 2015 USD ($)
AdvSP [Member]
Temporarily advanced	$ 95,000

XML 44 R34.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details)	Mar. 31, 2016 USD ($)
Aggregate future minimum payments under the lease including common area maintenance costs
2016 (remainder)	$ 145,670
2017	198,935
2018	204,585
2019	210,234
2020	106,530
Total	$ 865,954

XML 45 R35.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		3 Months Ended
	May. 06, 2016	Mar. 31, 2016	Mar. 31, 2015	May. 31, 2016	Apr. 30, 2016
Sublease		$ 16,637
Lease base rent		$ 49,913	$ 36,000
Increases in monthly lease payments, percentage		3.00%
Subsequent Event [Member]
Payroll tax withholdings and related employer taxes					$ 70,000
Back pay and penalties				$ 31,000
Payment for compensation	$ 49,998

XML 46 R36.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($)		3 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Apr. 04, 2016	Mar. 31, 2016	Mar. 31, 2015	May. 31, 2016	Dec. 31, 2015
Proceeds from notes payable		$ 244,975
Common shares issued		40,024,673			39,894,673
Subsequent Event [Member] \| Two employees [Member]
Options to purchase shares				1,000,000
Subsequent Event [Member] \| Two employees [Member] \| Minimum [Member]
Strike prices				$ 0.55
Subsequent Event [Member] \| Two employees [Member] \| Maximum [Member]
Strike prices				$ 1.50
Subsequent Event [Member] \| Canyon Assets Holdings, Inc. [Member]
Proceeds from notes payable	$ 575,000
Subsequent Event [Member] \| JTS Note [Member]
Face value of note	500,000
Accrued interest	75,000
Repayments of notes payable	$ 575,000
Interest rate	15.00%
Subsequent Event [Member] \| Gemini Master Fund, LTD [Member]
Proceeds from notes payable	$ 275,000
Face value of note	$ 275,000
Interest rate	8.00%
Common shares issued	50,000
Proceeds from notes payable, net of discount	$ 245,000
Maturity Date	Dec. 31, 2016
Default interest rate	18.00%
Convertible note description	The Gemini Note is convertible in part (subject to a $10,000 minimum) at the option of Gemini into shares of the Company’s common stock at the rate of $0.70 per share
Percentage of outstanding principal and all outstanding accrued interest	112.00%
Series of financings	$ 1,500,000
Conversion price	$ 0.25
Subsequent equity sales per share	$ 0.70

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 48 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 69 176 1 false 32 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://nugene.com/20140930/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://nugene.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://nugene.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://nugene.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://nugene.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION Sheet http://nugene.com/role/NatureOfBusinessAndBasisOfPresentation NATURE OF BUSINESS AND BASIS OF PRESENTATION Notes 6 false false R7.htm 00000007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://nugene.com/role/Note2-SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 00000008 - Disclosure - INVENTORIES Sheet http://nugene.com/role/Note3-Inventories INVENTORIES Notes 8 false false R9.htm 00000009 - Disclosure - INTANGIBLE ASSETS Sheet http://nugene.com/role/Note4-IntangibleAssets INTANGIBLE ASSETS Notes 9 false false R10.htm 00000010 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://nugene.com/role/Note5-PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 10 false false R11.htm 00000011 - Disclosure - PROMISSORY NOTES PAYABLE AND ADVANCES Notes http://nugene.com/role/PromissoryNotesPayableAndAdvances PROMISSORY NOTES PAYABLE AND ADVANCES Notes 11 false false R12.htm 00000012 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://nugene.com/role/Note6-StockholdersEquity STOCKHOLDERS' EQUITY Notes 12 false false R13.htm 00000013 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://nugene.com/role/Note7-RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 13 false false R14.htm 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://nugene.com/role/Note8-CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 14 false false R15.htm 00000015 - Disclosure - SUBSEQUENT EVENTS Sheet http://nugene.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 15 false false R16.htm 00000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://nugene.com/role/Note2-SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 16 false false R17.htm 00000017 - Disclosure - INVENTORIES (Tables) Sheet http://nugene.com/role/Note3-InventoriesTables INVENTORIES (Tables) Tables http://nugene.com/role/Note3-Inventories 17 false false R18.htm 00000018 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://nugene.com/role/Note5-PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://nugene.com/role/Note5-PropertyAndEquipment 18 false false R19.htm 00000019 - Disclosure - PROMISSORY NOTES PAYABLE AND ADVANCES (Tables) Notes http://nugene.com/role/PromissoryNotesPayableAndAdvancesTables PROMISSORY NOTES PAYABLE AND ADVANCES (Tables) Tables http://nugene.com/role/PromissoryNotesPayableAndAdvances 19 false false R20.htm 00000020 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://nugene.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://nugene.com/role/Note6-StockholdersEquity 20 false false R21.htm 00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) Sheet http://nugene.com/role/Note7-RelatedPartyTransactionsTables RELATED PARTY TRANSACTIONS (Tables) Tables http://nugene.com/role/Note7-RelatedPartyTransactions 21 false false R22.htm 00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://nugene.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://nugene.com/role/Note8-CommitmentsAndContingencies 22 false false R23.htm 00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://nugene.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://nugene.com/role/Note2-SummaryOfSignificantAccountingPoliciesPolicies 23 false false R24.htm 00000024 - Disclosure - INVENTORIES (Details) Sheet http://nugene.com/role/InventoriesDetails INVENTORIES (Details) Details http://nugene.com/role/Note3-InventoriesTables 24 false false R25.htm 00000025 - Disclosure - INTANGIBLE ASSETS (Details Narrative) Sheet http://nugene.com/role/IntangibleAssetsDetailsNarrative INTANGIBLE ASSETS (Details Narrative) Details http://nugene.com/role/Note4-IntangibleAssets 25 false false R26.htm 00000026 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://nugene.com/role/PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT (Details) Details http://nugene.com/role/Note5-PropertyAndEquipmentTables 26 false false R27.htm 00000027 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://nugene.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://nugene.com/role/Note5-PropertyAndEquipmentTables 27 false false R28.htm 00000028 - Disclosure - PROMISSORY NOTES PAYABLE AND ADVANCES (Details) Notes http://nugene.com/role/PromissoryNotesPayableAndAdvancesDetails PROMISSORY NOTES PAYABLE AND ADVANCES (Details) Details http://nugene.com/role/PromissoryNotesPayableAndAdvancesTables 28 false false R29.htm 00000029 - Disclosure - PROMISSORY NOTES PAYABLE AND ADVANCES (Details Narrative) Notes http://nugene.com/role/PromissoryNotesPayableAndAdvancesDetailsNarrative PROMISSORY NOTES PAYABLE AND ADVANCES (Details Narrative) Details http://nugene.com/role/PromissoryNotesPayableAndAdvancesTables 29 false false R30.htm 00000030 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://nugene.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details http://nugene.com/role/StockholdersEquityTables 30 false false R31.htm 00000031 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) Sheet http://nugene.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS' EQUITY (Details Narrative) Details http://nugene.com/role/StockholdersEquityTables 31 false false R32.htm 00000032 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://nugene.com/role/RelatedPartyTransactionsDetails RELATED PARTY TRANSACTIONS (Details) Details http://nugene.com/role/Note7-RelatedPartyTransactionsTables 32 false false R33.htm 00000033 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://nugene.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://nugene.com/role/Note7-RelatedPartyTransactionsTables 33 false false R34.htm 00000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://nugene.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://nugene.com/role/CommitmentsAndContingenciesTables 34 false false R35.htm 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://nugene.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://nugene.com/role/CommitmentsAndContingenciesTables 35 false false R36.htm 00000036 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://nugene.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://nugene.com/role/SubsequentEvents 36 false false All Reports Book All Reports nugn-20160331.xml nugn-20160331.xsd nugn-20160331_cal.xml nugn-20160331_def.xml nugn-20160331_lab.xml nugn-20160331_pre.xml true true ZIP 53 0001615774-16-005579-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001615774-16-005579-xbrl.zip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end